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Accurate dosing of anticancer drugs from the initiation of treatment is of paramount 
importance to the outcome of cancer therapy. Inappropriate dosing of anticancer drugs leads to 
therapeutic failure, toxicity, and drug resistance. Anticancer drugs have a narrow therapeutic 
index, that is the safety margin between therapeutically effective dose and toxic dose is very 
narrow. Also, wide inter-individual variability was reported in therapeutic responses to anticancer 
drug therapy. Currently, the doses of anticancer drugs are calculated based on the body surface 
area (BSA) of the patient.  The formulae for the determination of BSA were developed based on 
the studies in fewer subjects leading to inaccuracies both in the BSA determination and 
eventually in the dose calculation. Also, several studies have proven that the assumptions of BSA 
dosing methodology do not hold good for patients of different body sizes and for all drugs.  
Several alternative dosing equations were proposed but none of them could normalize the drug 
exposure of anticancer agents in disparate canine patients. Dogs have wide range of body weights 
ranging from 2.5 pound Chihuahua to 160 pound Saint Bernard for which, BSA dosing failed to 
normalize drug exposure for these widely variable patients.  
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The objective of this study was to develop novel dosing equation for the calculation of 
doses of anticancer drugs considering different anatomical and physiological parameters and drug 
kinetics which play an important role in deciding the dosage of anticancer drugs. Unlike other 
therapeutic drugs, the efficacy of anticancer drugs depends on the drug exposure and not on the 
peak concentration of the drug. For most of the drugs, liver and kidney are two primary organs of 
metabolism and excretion. Excretion of drugs occurs primarily by glomerular filtration and 
biliary secretion. Clearance of drugs is one of the important pharmacokinetic parameters which 
will influence the dose of a drug and is highly variable among patients leading to over-dosing or 
under dosing of anticancer drugs. For a given drug, if clearance is known, then dose can be 
accurately calculated for a desired drug exposure using the equation, Dose = (desired drug 
exposure) x (clearance).   
We hypothesized that the concomitant consideration of the effects of patient signalment 
such as, body weight, gender, and ontogeny on organ weights, physiological parameters, and 
anticancer drug handling will accurately predict the clearance of model anticancer drugs. In order 
to test our hypothesis, two model anticancer drugs were chosen: vinblastine and cisplatin. 
Vinblastine is a vinca alkaloid which is metabolized in the liver and excreted in bile/feces and to 
some extent in urine. Cisplatin [cis-Diamminedicholoroplatinum II, cis PtCl2(NH3)2] is a platinum 
containing alkylating agent. Cisplatin is metabolized in kidneys and excreted through urine. 
Vinblastine and cisplatin will serve as model anticancer drugs for other anticancer drugs having 
similar route of metabolism and excretion. 
The central hypothesis was tested by following specific aims:  
1. Determine the influence of individual factors, such as body weight, gender, and 
ontogeny on cardiac, hepatic and renal mass. 
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2. Determine the influence of body weight on renal and hepatic physiological 
parameters. 
3. Establish the relations between body size and intrinsic clearance of vinca alkaloids. 
4. Establish the relations between body size and total body clearance of selected model 
anticancer drugs. 
5. Establish correlations between in vitro and in vivo clearance of selected anticancer 
drugs.  
6. Create an improved mathematic model for calculating doses of model anticancer 
drugs and compare the newly developed dosing equations to the current BSA dosing 
method.  
Our hypothesis and specific aims to test hypothesis in question were innovative in 
approach. Our approach integrates separate fields of anatomy, physiology, pharmacology, and 
oncology to come up with novel dosing equations which would normalize drug exposure in 
disparate canine patients.  Attempts were made to develop novel dosing equations that would 
optimize the drug exposure between disparate canine patients. We are also anticipating to 
extrapolate results from this study to other anticancer drugs that are similarly metabolized and 
excreted from the body. The long term goal of our lab is to extrapolate the resulting equations to 
human beings as human oncologists also face similar problems in optimizing doses of anticancer 
drugs. 
In this dissertation, the studies were categorized based on manuscript format. A 
manuscript on ‘Allometric Scaling of Renal Clearance of Cisplatin in Dogs’ was summarized in 
chapter III. In chapter IV, ‘Allometry of Hepatic Metabolism of Vinblastine in Dogs’ was 
presented. In chapter V, analytical method development manuscript, ‘Simultaneous 
4 
 
Quantification of  Vinblastine and Desacetylvinblastine Concentrations in Canine Plasma and 











1. Anticancer drugs:  
Cancer is one of the major causes of death both in human and animals. Chemotherapy 
alone or in combination with other therapies is an important approach for cancer treatment. 
German bacteriologist, Paul Erlich is considered to be the father of chemotherapy who received 
Nobel Prize in 1908 for his studies on effects of chemicals on tissues and treatment of syphilis. 
Anticancer drugs are characterized by narrow therapeutic index (Hempel and Boos, 2007). 
Narrow therapeutic index means the safety margin between therapeutically effective dose and 
toxic dose is very narrow. Development of drug resistance is another issue in chemotherapy. 
Therefore, in order to achieve optimal therapeutic efficacy, most of the cytotoxic drugs are 
administered at the maximum tolerated dose (MTD) (Hempel and Boos, 2007). Also, individuals 
have a highly variable capacity to metabolize and eliminate drugs, which comes from a 
combination of physiological variables, genetic (intrinsic) characteristics, and individual’s 
phenotype. Unlike many therapeutic drugs, the efficacy of anticancer agents correlates with the 
drug exposure (Moore and Erlichman, 1987; van den Bongard et al., 2000). Mathematically, drug 
exposure is calculated as area under plasma concentration versus time curve (AUC)(Calvert et al., 
1989; Hempel and Boos, 2007). The systemic drug exposure after standard doses of cytotoxic 
drugs varies 4 – 10 folds between patients (Evans and Relling, 1989; Masson and Zamboni, 
1997). There are several reasons for variation in systemic drug exposure in patients and were 
summarized in Figure 1 (Mathijssen et al., 2007). In addition, many anticancer drugs have unique 
and peculiar pharmacokinetic and pharmacodynamic profiles. This results in variable therapeutic 
outcome with the same dose in similar patients.  
The major classes of commonly used anticancer drugs: (Hess, 1977) 
Antimicrotubule agents: These agents are cell cycle specific and induce metaphase arrest. They 
act by destroying the mitotic spindle of the cell and preventing further cell division. Also, disrupts 
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other tubulin dependent events, such as intracellular transport, organelle movement, and 
membrane trafficking E.g., vinca alkaloids, such as vinblastine, vincristine, vinflunine, vindesine 
and vinorelbine; taxanes, such as paclitaxel and docetaxel. 
Antimetabolites: These agents interfere with the biosynthesis of nucleic acids by substituting for 
normal metabolites and inhibiting normal enzymatic reactions. E.g., 5-fluorouracil, methotrexate 
Alkylating agents: These agents act by crosslinking cellular DNA, thus arresting its ability to act 
as a template for RNA synthesis. These are not cell cycle specific. E.g., cyclophosphomide, 
lomustine, cisplatin, carboplatin, and oxaliplatin. 
Topoisomerase inhibitors: These agents act by inhibition of  topoisomerase II and causing DNA 
strand breaks. E.g., doxorubicin, epirubicin, daunorubicin, etoposide, and teniposide. 
Enzyme therapy: These agents act by depletion of asparagines, on which leukemic cells depend. 
E.g., asparginase 
Hormone receptor therapy: these agents are thought to act by interfering with cell membrane 
receptors that stimulate growth. E.g., tamoxifen, leuprolide acetate, and megestrol acetate 
Tyrosine kinase inhibitors: These agents act by inhibition of c-kit. E.g., toceranib phosphate, 
imatinib, mastinib, erlotinin, and gefitinib. 
Cell cycle:  
Normal cells have four basic properties, such as ability to proliferate, capacity for self-renewal, 
ability to differentiate, and sensitivity to regulatory mechanisms. On the other hand, tumor cells 
have ability to proliferate and capacity for self-renewal without control. Cytotoxic agents work on 
the more proliferating cells. Some of the cytotoxic agents are cell cycle specific and knowledge of 
the cell cycle or the proliferative state of the cell populations is important to understand the 
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cytotoxic effects of cancer chemotherapy. Figure 2 is an illustration of different phases of cell 
cycle (Hess, 1977; Alberts et al., 2002). The cell cycle is divided into following stages: G0 = 
resting phase; G1 = protein synthesis; RNA transcription; S = DNA synthesis; G2 = protein 
synthesis; RNA transcription; M = Mitosis; and G1+S+G2 = Interphase. The goal of the treatment 
is to kill tumor cells without hurting normal cells. Cells in S-phase are particularly susceptible to 
cytotoxic treatment affecting the formation of nucleotides and inhibition of DNA repair. Rapidly 
growing tumors are more susceptible to treatment compared to resting tumor cells. The favorable 
prognosis of a tumor with chemotherapy is inversely proportional to the tumor population.   
Adverse drug reactions and dose limiting toxicities of cytotoxic drugs: 
Anticancer drugs are characterized by narrow therapeutic index. That is, the safety margin 
between therapeutic effective dose and toxic dose is very narrow. For an example, the minimum 
lethal dose of cisplatin in dogs is 2.5 mg/kg (≈80 mg/m
2
) (Schaeppi et al., 1973) while the 
therapeutic dose is 60 – 70 mg/ m
2 
(Knapp et al., 1988). Understanding about potential toxicities 
associated with chemotherapy is important in determining the maximum tolerated doses (Chatelut 
et al., 2003). Dose dependent toxicity is seen with several anticancer drugs. On the other hand, if 
doses are administered below maximum tolerated doses, then drug resistance will develop 
(Powis, 1983). Gametes, gastrointestinal epithelium, hair follicles, bone marrow progenitor cells 
are highly dividing normal cells in the body. Chemotherapeutic drugs are most effective on 
highly dividing tumor cells. Therefore, cytotoxic drugs also act on normal highly dividing cells 
along with neoplastic cells. The common toxicities associated with chemotherapy are bone 
marrow depression, lymphocytopenia, gastrointestine tract (GIT) disturbances, diarrhea, alopecia, 
hyperuricaemia, nausea, and vomiting. Among these toxicities, bone marrow depression, 
alopecia, and gastrointestinal disturbance are the most common side effects of chemotherapy, 
commonly known with an acronym, B-A-G. Also the organ systems in which metabolism and 
excretion of chemotherapeutics occur are also highly susceptible to chemotherapy toxicity 
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(Erdlenbruch et al., 2001; Barabas et al., 2008). Most of these adverse drug toxicities and dose 
limiting toxicities are dependent on the mechanism of action of each chemotherapeutic agent. 
Dosing strategies: 
Chemotherapy is most effective when initiated as soon as possible after diagnosis of a tumor. The 
proportion of cells killed by chemotherapy is greater when tumor cells are less in number. Also, 
the regrowth of tumor population is more when the number of tumor cells are fewer (Foote, 
1998).  With the toxicity of chemotherapy, usually planned doses are reduced or delayed but this 
change in dosing regimen will have great impact on the therapeutic outcome. Figure 3 shows the 
effect of dose intensity of chemotherapy on tumor cell kill and regrowth between cycles (Norton, 
1997; Foote, 1998). Gompertzian model of tumor growth suggests that tumor growth is highest 
when the size of tumor is small. Also, between treatment cycles, regrowth of tumor cells will be 
more. The best approach would be to dose at the maximum tolerated doses at the shortest possible 
dosing intervals while monitoring the toxicity. 
Drug resistance: 
Development of drug resistance to anticancer agents is another big issue in addition to 
their narrow therapeutic indices. The mechanisms of drug resistance are (figure 4):  development 
of alternative metabolic pathways and repair mechanisms; destruction of drug by the cell; 
changes in the permeability of the cell membrane or altered p-glycoprotein pumps; tumor cells 
entering the resting phase of the cell cycle; and deletion of cellular drug activation mechanisms 
(Gottesman, 2002; Rabik and Dolan, 2007). Unfortunately, normal cells do not develop drug 
resistance on par with tumor cells. Synergistic effects of combinations of cytotoxic agents were 




2. Dosing of Anticancer Drugs: 
Current dosing methodology for anticancer drugs: 
The doses of anticancer drugs are calculated based on the body surface area 
(BSA)(Ratain, 1998). Appropriate doses of drugs are calculated based on pharmacokinetic 
parameters, but these parameters differ highly for anticancer agents between patients. In an 
attempt to normalize doses of anticancer drugs between different body sizes, BSA based dosing 
was suggested based on studies with 6-mercaptopurine, actinomycin-D, and 
triethylenethiophosphoramide in different animal species and humans (Pinkel, 1958). The dose 
normalized to body surface area appeared to be more uniform across different animal species and 
humans. In clinical medicine, body surface area based dosing approach was used for the 
determination of amount of parenteral fluids and electrolytes administration. The daily normal 
water requirement of the young infant (100 mL/kg) and adult (50 mL/kg) were both met by 
administration of 2 liters of water per square meter of body surface (Baker et al., 1957). The 
rationale for Pinkel’s approach was based on earlier studies in which metabolic rate appeared to 
be directly proportional to body surface area and vary allometrically with body weight (DuBois 
and DuBois, 1916). Later, correlations were found between body surface area and different 
physiological parameters, such as renal function (glomerular filtration rate), cardiac output, and 
hepatic blood flow (Coppoletta and Wolbach, 1933; Kanamori et al., 2002). These findings 
suggested that BSA might have value in calculating the doses of anticancer agents.(Fukuoka et 
al., 2004)  
BSA based dosing and limitations: 
Although BSA based dosing is intuitively logical and simple to understand, there were 
several studies that reported toxicities and questioned its ability to explain the disposition of 
several anticancer drugs (Mathijssen et al., 2007) Jones et al., 1984; Page et al., 1988; Arrington 
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et al., 1994). It was found that BSA based dosing did not reduce the variability of drug exposure 
(AUC, area under plasma concentration versus time curve) among disparate patients.  The 
assumptions that were made for BSA dosing methodology were also proven to be inaccurate, 
such as glomerular filtration rate (GFR) (Dooley and Poole, 2000), hepatobiliary excretion system 
and liver function (Arrington et al., 1994; Gurney, 1996). Bone marrow toxicity is one of the 
common side effects of chemotherapy. It was shown that the number of hematopoietic stem cells 
is proportional to body weight but not BSA (Vriesendorp, 1985). Unless the metabolism or 
excretion of drug is increased in small animals, their bone marrow stem cells would be exposed to 
larger concentrations of drug for a longer period when dosed by BSA - based dosing 
(Vriesendorp, 1985; Arrington et al., 1994). A number of studies examining pharmacokinetic 
parameters have also questioned the application of BSA as a means of individualizing 
chemotherapeutic doses (Grochow et al., 1990; Gurney, 1996; Gurney et al., 1998; Dooley and 
Poole, 2000; Felici et al., 2002).  In one investigational study to see the suitability of BSA dosing 
approach in 33 anticancer agents, BSA dosing reduced interpatient variability only for five drugs, 
namely docosahexaenoic acid-paclitaxel, 5-fluorouracil/eniluracil, paclitaxel, temozolomide, and 
troxacitabine (Baker et al., 2002). Docetaxel is the only drug for which BSA is the good predictor 
of drug clearance. (Felix et al., 2001;Bruno et al., 1998). Furthermore, the drugs for which 
clearance was associated with BSA, the relative reduction in variability of clearance was between 
15% and 35%. This means, only one third of the total variability could be explained by BSA 
(Baker et al., 2002; Miller, 2002). Blood volume, total body water (TBW) and extracellular water 
(ECW) are better correlated with the BSA than body weight (Baker et al., 1957). Accordingly, 
BSA based dose calculations would seem rationale for the drugs which are distributed in the 
central compartment and having low volume of distribution (Baker et al., 1957; Friis-Hansen, 
1961; Felici et al., 2002). 
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BSA is estimated based on nomograms or computer programs that contain Du Bois and 
Du Bois  formula. Several questions have also arisen on the equations to calculate body surface 
area in both humans and animals. The widely used Dubois and Dubois equation was developed 
based on studies in nine individuals (DuBois D and EF, 1916; Du Bois and Du Bois, 1989). 
Several alternative equations and methods were proposed to measure BSA in both humans and 
animals but none of them were free of disputes (Haycock et al., 1978; Sawyer and Ratain, 2001; 
Wang and Hihara, 2004; Verbraecken et al., 2006). There is also a confusion regarding which 
body weight (ideal, lean  or actual body weight)  should be used for the calculation of BSA 
(Dooley and Poole, 2000). In other words, BSA calculations do not consider the question whether 
a kilogram of fat is equivalent to a kilogram of muscle or of lower-extremity edema (Egorin, 
2003). 
The equation to calculate BSA in humans: BSA (m
2
) = W 
0.425
 x H 
0.725
 x 0.007184 where 
W = weight in kilograms, H = height in centimeters (DuBois and DuBois, 1916). The following 
equation is widely used to determine the BSA in dogs: BSA (m
2





.  There are approximately 400 breeds of dogs worldwide out of which, 156 were 
recognized by American Kennel Club (http://www.akc.org/breeds/complete_breed_list.cfm). As 
there are several breeds of dogs and body weights of dog breeds range from 2 pounds to 200 
pounds, different values of mass co-efficient and mass exponents were suggested (Cowgill and 
Drabkin, 1927; Price and Frazier, 1998).  A single value of mass co-efficient will not be sufficient 
for a wide range of body weights in dogs. Further, different values were suggested for cats, rats, 
and guinea pigs which have relatively uniform body conformation (Price and Frazier, 1998). 
Canine breeds differ markedly in their conformation and it would be more obvious to have 
different values of mass co-efficient. Similarly, different values were suggested for mass 
exponents (Cowgill and Drabkin, 1927; Price and Frazier, 1998). It might be that even if BSA is 
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determined accurately, it may not correlate with the factors that influence the drug exposure in 
dogs. 
There is a continuous need from both veterinary and human oncologists for a better 
alternative to current BSA based dosing. Different alternative dosing methodologies were 
suggested (Gurney, 1996; Canal et al., 1998) to overcome the limitations in BSA based dosing, 
such as body weight (Page et al., 1988; Arrington et al., 1994), flat fixed dosing (Hempel and 
Boos, 2007; Mathijssen et al., 2007), fixed dosing for BSA clusters (Loos et al., 2006), 
therapeutic drug monitoring, toxicity adjusted dosing, and etc. However, these alternative dosing 
methodologies worked only for one or few drugs but the toxicity adjusted dosing is more popular. 
As there is a wide variability in therapeutic outcome with chemotherapy, toxicity adjusted dosing 
could be useful to attain optimal therapeutic efficacy (Rassnick et al., 2008; Welle et al., 2008). In 
humans, dosing based on renal functional marker was successfully implemented for carboplatin, a 
sister analogue of cisplatin (Calvert et al., 1989). As there is no widely accepted alternative 
dosing methodology, currently BSA based dosing is being used for initial dose calculation of 
several drugs.  
Allometry: Allometry is the study of relationship between body size and structural or functional 
capacities of organs(Jurgens and Prothero, 1991). The word, ‘allometry’ was coined by Huxley 
and Tessier in 1936. Allometry is opposite to isometry, which means ‘by the same measure’ 
whereas allometry means ‘by a different measure’. Geometrically similar objects are often called 
isometric. In isometric relationship, the proportion remains the same whereas in allometric 
relationship, the proportions are altered in a regular manner. In other words, this change in a 
specific parameter correlates with differences in size of the organism (Mahmood, 2007).  Several 
anatomical (BSA, liver weight, kidney weight, and other organs), physiological (basal metabolic 
rate, glomerular filtration rate, renal blood flow, and cardiac output), and pharmacokinetic 
parameters (clearance, volume of distribution, and elimination half life) depend on body weight 
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with allometric relationship.  Figure 5 illustrates the allometric relationship. As the volume of the 
cube increases, surface area also increases but not in direct proportion. Surface area becomes 
disproportionately smaller in relation to the volume of larger cubes. If the surface area of a cube 
is plotted against the volume on logarithmic coordinates, the slope will be 0.67. If the surface area 
per unit volume of the cube is plotted (dashed line) against volume of cube, then the slope of the 
regression line will be -0.33 (figure 6).  
S= k x V
0.67
 
S/V = k V
0.67
/V  
        = k V
0.67 - 1.0
 
S/V = k V
-0.33
  
As a consequence, smaller bodies have, relative to their volumes, larger surface areas than larger 
bodies of the same shape (figure 5). Based on these observations for geometrically similar 
objects, it was considered that intraspecific (allometric scaling within a species) exponent is 0.67 
(Hoppeler and Weibel, 2005). On the other hand, based on interspecies scaling of basal metabolic 
rate in mammals and birds, it was assumed that 0.75 is the exponent of interspecies allometric 
scaling (Schmidt-Nielsen, 1984; Hoppeler and Weibel, 2005). Three – fourth allometric exponent 
of interspecies scaling is widely accepted based on the structure and design of vascular system 
(West et al., 1997). However, over the last century, several studies questioned these exponents of 
intraspecies and interspecies scaling (Ritschel et al., 1992; White and Seymour, 2003; Hoppeler 
and Weibel, 2005; White and Seymour, 2005).  
3. Scaling of organ weights in dogs 
Intraspecies allometric scaling is the study of allometric relationship between structural 
and functional capacities of organs in relation with the body weight within a species.  Study of 
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allometric relationship between organ weights and body weights is important in estimating the 
organ weights in species like dogs, in which there is a wide variation in body weights. There are 
several utilities of organ weight estimations,  such as estimation of organ volume or size for 
surgery and organ transplantation(Gregory et al., 1987), incorporation of allometric equations in 
population based pharmacokinetic and physiological based pharmacokinetic (PBPK) software 
programs, and to differentiate between normal and pathological lesions in autopsy . Most of the 
previous studies of organ scaling were limited to either few numbers of subjects or uniform 
subjects (Jackson and Cappiello, 1964; Deavers et al., 1972; Steward et al., 1975; Lutzen et al., 
1976; Steel et al., 1976; Schoning et al., 1995). In dogs, there is an approximate 100 fold 
difference in their weights. The existing studies would not be helpful to estimate the organ 
weights with good accuracy. Also, most of the studies are based on fixed proportion of body 
weights rather than allometric relationships (Jackson and Cappiello, 1964; Nemec and Vortel, 
1981). Heart, liver, and kidney are three important organs which play direct or indirect role in the 
metabolism and excretion of many therapeutic drugs. Human and veterinary pathologists estimate 
heart, liver, and kidney weights as 0.75%, 3.5%, and 0.4% (juvenile) and 1.13% (adult) of body 
weights, respectively(Steward et al., 1975). However, these fixed proportions of body weights 
may not give good estimates of organ weights in dogs because of their wide variation in body 
conformation within the species. Fixed proportion of body weights approach gives mean value of 
proportion of an organ weight to body weight. Allometric equations give good estimate of organ 
weights as a function of all significant factors in the multiple linear regressions.  
4. Renal physiological parameters 
Kidneys are one of the most complex organs in the body which play a gamut of 
biological roles. The main role is maintenance of homeostasis of body fluids by filtering and 
secreting metabolites and minerals from the blood and excreting them, along with water, as urine. 
This is achieved by glomerular filtration, tubular reabsorption and tubular secretion. Renal blood 
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flow accounts for 20-25% of the cardiac output.  In a 15 kg dog about 200 ml of fluid enters renal 
tubules per min (60 L/day). The animal produces only about 600 ml of urine per day, indicating 
most of the glomerular filtrate is reabsorbed rather than excreted. The other important functions 
of kidneys are blood filtering, excretion of waste products, homeostasis, acid-base balance, and 
maintenance of blood pressure and plasma volume, and hormone secretion.  
Glomerular filtration rate: 
 Glomerular Filtration Rate (GFR) is defined as the volume of plasma that can be 
completely cleared of a particular substance by the kidneys in a unit of time. The main factors 
that influence GFR are molecular size, protein binding, glomerular integrity, resistance of afferent 
and efferent arterioles, and total number of functional nephrons. The basis of urine formation is 
the ultrafiltration of plasma in the glomerulus. A measure of the magnitude of this filtration 
therefore is generally accepted to be the best overall index of renal function. Accurate GFR 
determination may facilitate prognostic decisions in patients with established renal disease. GFR 
estimation is useful in therapeutic drug monitoring of several drugs with narrow therapeutic 
index. GFR is useful in old and critically ill patients to make drug dosage adjustments. 
Glomerular filtration rate in the dog may be influenced by several nonrenal factors such as 
protein intake, hydration status, sodium balance, gender, age, and breed, as well as day-to-day 
and circadian variations for the individual dog (Finco et al., 1981; Izzat and Rosborough, 1989; 
Levey, 1989; Gleadhill et al., 1995; Koopman et al., 1996). Thus, the range of reference values in 
healthy dogs is wide. 
Different methods which are commonly used to measure GFR are: inulin clearance (Earle 
and Berliner, 1946), blood urea nitrogen (BUN) , creatinine (Jung et al., 1987; Lawson et al., 
2002; Braun et al., 2003), radioactive isotopes (
125
I-iothalamate (Boschi and Marchesini, 1981; 










EDTA) (Rehling et al., 1984; Effersoe et al., 1990)), radiographic contrast media (Frennby and 
Sterner, 2002), and cystatin C (Tenstad et al., 1996; Laterza et al., 2002).  
Glomerular filtration rate (GFR) cannot be measured directly but rather is estimated using 
the clearance of a filtration marker. The GFR is equal to the renal clearance (CLrenal) of a filtration 
marker if the marker is not protein bound, does not enter red blood cells, and is only excreted 
through the kidney solely by filtration, with neither tubular secretion nor reabsorption. In 
addition, the substance must not be toxic and must not in itself alter GFR. For such a substance, 
CLplasma equals CLrenal. Renal clearance of surrogate marker of GFR is calculated by using the 
classical formula, CLrenal = ( U x Cu ) / Cp,  which was introduced by (Rehberg, 1926) where U = 
urine flow in mL/min,  Cu = marker concentration in urine in mg/mL,  and Cp = marker 
concentration in plasma in mg/mL. This approach is accurate provided urine collection is 
complete. In practice, it is often difficult to make sure that the bladder is empty after urine 
collection, and incomplete bladder emptying will lead to underestimation of GFR (Finco, 2005). 
Risk of infection due to catheterization is also a complicating factor.  
  Estimation of renal clearance by the classical formula from blood and urine data has been 
the most common approach, but the use of CLplasma methods is becoming more common these 
days to shorten the time of assay and to avoid tedious urine collection process. Plasma clearance 
is calculated by using either  CLplasma= D/AUC, where D = dose of marker and AUC = area under 
the plasma concentration versus time curve or ratio of infusion rate of inulin to plasma steady 
state concentration of inulin,              
                               ⁄
            ⁄
⁄   (Fischer P.A et 
al., 2000) 
Inulin clearance:  
 Inulin is a fructose polysaccharide which is mainly obtained from tubers of Dahlia and 
Chicory, and dozens of other tubers, roots and artichokes of plants (figure 7). Inulin is non-toxic, 
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completely freely filtered by glomerular filtration, neither absorbed nor secreted by renal tubules 
(Earle and Berliner, 1946; Richards and Hoe, 1967; Perrone et al., 1990; Prescott et al., 1991). 
Therefore, renal clearance of inulin using continuous infusion is generally considered to be the 
gold standard for the measurement of GFR (Earle and Berliner, 1946; Brochner-Mortensen, 
1985). If a new marker is introduced, it is common to compare the results to CLrenal of inulin for 
validation of the new method (Brenner et al., 1976). Inulin must be administered intravenously 
since it is hydrolyzed to fructose in the gastrointestinal tract and is erratically and poorly absorbed 
from subcutaneous or intramuscular routes of administration. The classical method of measuring 
urinary clearance includes intravenous administration of a priming dose followed by a constant 
infusion of inulin (Smith et al., 1938). Under these conditions, plasma and urine inulin 
concentrations reach a constant level, which is equal in arterial and venous blood. After an 
equilibration period of approximately 60 - 80 minutes, several blood and urine samples are 
collected ranging from 10 - 20 minute intervals. Then, GFR is calculated by using the standard 
formula:  CLrenal = ( U x Cu ) / Cp where U = urine flow in mL/min,  Cu = marker concentration in 
urine in mg/mL,  and Cp = marker concentration in plasma in mg/mL. The need for timed urine 
collection is obviously cumbersome and pretends to be a great limitation for routine measurement 
of GFR in the classical urinary clearance of inulin method. In the recent years, plasma clearance 
of inulin has been introduced in the veterinary medicine as a promising alternative for estimating 
GFR in a clinical setting (Fettman et al., 1985; Rogers et al., 1991; Brown et al., 1996; Miyamoto, 
1998). For the measurement of plasma inulin clearance, inulin is given either as a constant 
intravenous infusion alone or followed by infusion of a bolus dose. When plasma or serum levels 
of inulin reach steady state during an intravenous infusion of the compound, the rate of excretion 
is equal to the rate of infusion. From this assumption,  GFR (mL/min) = Rate of infusion 
(mg/min) / Cp(ss)  (mg/mL) [where Cp(ss) is the plasma steady state concentration of inulin] (Shnurr 
et al., 1980; Fischer P.A et al., 2000). It has been shown that the plasma clearance of inulin values 
are overestimated than urinary clearance values (Hellerstein et al., 1993; Van Acker et al., 1995). 
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The reason for overestimation of GFR values is due to failure to obtain constant inulin plasma 
concentrations during intravenous infusion. The error would be pronounced if the shorter infusion 
times were chosen (Rahn et al., 1999).   
Most of the analytical methods used for the quantification of inulin are based on the acid 
hydrolysis. Several substances such as resorcinol, anthrone, diphenylamine and indole-3-acetic 
acid, have been used and the color formed from the reaction with fructose was measured 
photometrically. The colorimetric assays are often inaccurate, mainly due to interference from 
plasma hexoses and potentially dangerous owing to the use of concentrated corrosive reagents 
(Heyrovsky, 1956; Fjeldbo and Stamey, 1968). Other methods involving the use of enzymatic 
procedures after acid hydrolysis are time consuming. Analysis of inulin in plasma and urine 
samples after acid hydrolysis by reversed phase HPLC gave good results (Dall'Amico et al., 
1995; Pastore et al., 2001).  
The limitations of inulin clearance as a surrogate marker of GFR are: Inulin has a 
relatively high molecular weight and it takes quite a long time to attain equilibration (Hellerstein 
et al., 1993). Furthermore, there is no commercially available sterile inulin preparation which can 
be used readily. Each lab or clinic has to prepare and standardize to their conditions. 
Anaphylactic reactions have reported with the administration of inulin (Bacchetta et al., 2008a; 
Bacchetta et al., 2008b). Because of lack of alternative methods which could measure GFR with 
maximum accuracy, inulin clearance is still considered as gold standard for the measurement of 
GFR.  
Effective Renal Plasma Flow (ERPF): 
 Renal plasma flow is estimated from the clearance of a compound that is almost 
completely extracted from the renal blood. Since no compound is totally extracted in a single 
pass through the kidney, the measurement of renal plasma flow realistically falls slightly below 
the actual renal plasma flow, and thus is known as effective renal plasma flow (ERPF). Para 
amino hippuric acid (PAH) (N-(4-aminobenzoyl)-glycine) (figure 8) is an organic anion that is 
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freely filtered by the glomerulus and extensively secreted into the proximal convoluted tubule by 
active transport and very poorly reabsorbed into the tubules. The secretion of PAH is so 
effective that 90% or more of the PAH in renal arterial plasma may be removed in a single 
passage through the kidney. In practice, the concentration of PAH in renal venous plasma is 
ignored and the concentration of PAH in peripheral venous plasma is taken as an estimate of the 
renal arterial plasma PAH concentration. As PAH is removed from the blood exclusively by the 
kidney and is nearly completely cleared from the renal plasma in one passage through the 
kidney, the renal clearance of PAH is approximately equal o the total effective renal plasma flow 
(Shnurr et al., 1980; Mann and Kinter, 1993). ERPF is determined following administration of 
bolus dose and intravenous administration of PAH for approximately 180 minutes or until steady 
state is achieved. Plasma samples are collected during the steady state and concentrations of 
PAH are determined to calculate ERPF and ERBF using the following equations (Mann and 
Kinter, 1993; Fischer P.A et al., 2000): 
              
                            ⁄
               ⁄
⁄  
              
                            ⁄
                   ⁄  
⁄  
The clearance of PAH depends on the rate of delivery of PAH to the kidney. This 
transport mechanism is ATP dependent and saturable. Delivery of PAH into the proximal tubule 
in excess of the maximal rate of PAH (Tm, or transport maximum) results in incomplete 
extraction and spillage of PAH into the renal venous plasma. This results in underestimation of 
renal blood flow and will approach the values of GFR (Mann and Kinter, 1993). Earlier 
analytical methods to measure PAH by colorimetric reaction was often difficult and frequently 
inaccurate in the presence of glucose and other drugs (Boschi and Marchesini, 1981).  Recent 
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advancement in chromatography techniques have lead to development of good analytical 
methods using HPLC (Baccard N et al., 1999 ; Brenna et al., 1998 )  
Other methods for measurement of ERPF: electromagnetic, ultrasonic and Doppler flow 
probes placed directly on the renal artery; magnetic resonance imaging; using radioactive tracers, 
such as 
131
I orthoiodohippurate (OIH), 
99m
Tc-mercaptoacetyl-triglycine (MAG3) (Itoh, 2001). 
5. Vinblastine 
 Vinblastine (vincaleucoblastine, VLB) is a vinca alkaloid isolated from periwinkle plant, 
Catharanthus roseus (family: Apocyanaceae). Vinca alkaloids consist of indole nucleus 
(catharanthine) and dihydroindole nucleus (vindoline portion) (figure 9). Vinblastine was the first 
vinca alkaloid isolated. Its clinical use was first discovered when leucopenia was noticed after 
consumption of leaves of periwinkle plant in tea. This led to hypothesis that vinblastine might be 
useful to treat white blood cell cancers, such as lymphoma. In order to increase the therapeutic 
utility and decrease the potential for toxic side effects, semi-synthetic vinca alkaloids, such as 
vinflunine, vindesine sulfate, and vinorelbine (VRB) were developed (Damen et al., 2010). 
Although all of these vinca alkaloids share common features in their structure and affinity for 
microtubules, there is variability in their therapeutic efficiency, therapeutic indications, and 
toxicities (Damen et al., 2009).   
Vinca alkaloids bind to beta - tubulin and inhibit the assembly of microtubules during M 
phase of cell cycle (figure 2). Microtubules are highly dynamic cytoskeleton fibers that are 
composed of tubulin subunits (Pasquier and Kavallaris, 2008).  For the separation of 
chromosomes during anaphase of mitosis, microtubules - an important component of the mitotic 
spindle, and kinetochore are necessary.  This binding of tubulin results in arrest of mitosis 
(Schneider-Affeld et al., 1977; Hashizume et al., 1988; Jordan and Wilson, 2004; Gan and 
Kavallaris, 2008; Kavallaris et al., 2008; Cheng et al., 2009).   
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Development of resistance to microtubule targeted drugs have several possible 
mechanisms including changes in microtubule dynamics as a result of altered expression of 
tubulin isotypes, tubulin mutations, and altered expression or binding of microtubule regulatory 
proteins (Jordan and Wilson, 2004). 
Vinblastine is effective against soft tissue tumors, such as lymphomas, carcinomas, 
splenic tumors, and mast cell tumors as a single agent or in combination with other anticancer 
drugs. Vinblastine is administered intravenously. Oral absorption of vinblastine is erratic and 
incomplete (Golden and Langston, 1988; Camps-Palau et al., 2007; Vickery et al., 2008). 
Reversible myelosuppression and peripheral neuropathy (Park et al., 2008) are the 
principle side effects of vinblastine chemotherapy.  In vinblastine treated patients, dose related 
granulocytopenia with a nadir at 4 to 9 days after treatment and recovery in 2 to 3 weeks is 
commonly seen. Gastrointestinal signs, malaise, weakness, and alopecia may be seen. Because of 
the pattern of myelosuppression associated with vinblastine, dosing regimens include biweekly 
administrations preceded by WBC counts (Bailey et al., 2008).  
Vinblastine is primarily metabolized by cytochrome P450 enzymes in the liver and 
eliminated in feces (Creasey et al., 1975; Chabner et al., 1977). Urinary excretion of vinblastine is 
minimal compared to biliary route (Creasey et al., 1975; de Lannoy et al., 1994). Vinblastine is 
metabolized to desacetylvinblastine (figure 10) which is presumed to be pharmacologically 
active. 
Different analytical methods were developed using reversed phase high performance 
liquid chromatography(De Smet et al., 1987; van Tellingen et al., 1991; Volkov and 
Grodnitskaya, 1994), radioimmunoassay, liquid chromatography – tandem mass spectrometry 
(LC/MS/MS) (Ramirez et al., 1997; Zhou et al., 2005; Damen et al., 2008) to quantify vinblastine 




Cisplatin (cis-diamminedichloroplatinum (II) (CDDP); cis-PtCl2(NH3)2is a platinum 
containing alkylating agent indicated for the treatment of solid tumors (figure 11). The cytotoxic 
effects of platinum were discovered while studying the effects of electrical current on bacterial 
growth (Rosenberg et al., 1965) . The mechanism of action of cisplatin is by establishing cross 
links within and between purine bases. Intrastand cross linking between Guanine – Guanine 
association was shown to be more common than other linking (Bellon et al., 1991). Cisplatin is 
indicated for the treatment of several solid tumors in both humans and dogs including but not 
limited to ovarian, testicular, transitional cell tumor, germ cell tumors, osteosarcomas, 
neuroblastomas, medulloblastomas (Pinkerton et al., 1986; Peng et al., 1997; Greene et al., 2007; 
Fouladi et al., 2008). Cisplatin is a powerful emetic and requires antiemetic therapy prior to 
administration of cisplatin. Ondansetron has shown to be a potent antiemetic in cisplatin 
administration. Nephrotoxicity is the  dose limiting toxicity of cisplatin (Daugaard et al., 1987a; 
Daugaard et al., 1987b; Erdlenbruch et al., 2001; Barabas et al., 2008; Townsend et al., 2009). 
Therefore, saline diuresis prior to and after cisplatin administration is necessary to reduce 
possible nephrotoxicity. Cisplatin is contraindicated in cats as it causes fatal pulmonary edema.  
Cisplatin is given intravenously and some studies have shown efficacy with intralesional injection 
with sesame oil or epinephrine gel. Many mechanisms of cisplatin resistance have been proposed 
including changes in cellular uptake and efflux of the drug, increased detoxification of the drug, 
inhibition of apoptosis and increased DNA repair (Rabik and Dolan, 2007). 
Carboplatin is sister analogue of cisplatin with reduced nephrotoxicity and non-emetic. 
Carboplatin can be used in cats unlike cisplatin. Carboplatin replaced cisplatin in veterinary 
medicine. However, cisplatin is still considered for treating several solid tumors because of its 
efficacy against several tumors both in humans and dogs (Fouladi et al., 2008). Carboplatin is 
more expensive than cisplatin. Unlike cisplatin, the clearance of carboplatin correlates with the 
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glomerular filtration rate in humans (Calvert et al., 1989; de Jongh et al., 2001). In humans, 
creatinine clearance was used as a surrogate marker of glomerular filtration rate (GFR) and an 
equation was developed retrospectively to calculate the doses of carboplatin more accurately as a 
function of creatinine clearance.   
Dose (mg) = target AUC (mg.min/mL) x (GFR [mL/min] + 25) 
Where the target AUC is 5 – 7 mg.min/mL for previously untreated patients receiving single 
agent carboplatin; or 4 – 6 mg.min/mL for previously treated patients receiving single agent 
carboplatin or previously untreated patients receiving carboplatin plus cyclophosphomide 
(Calvert et al., 1989).  
7. Mast cell tumors 
Mast cells are normal components of different tissues throughout the body. They are 
round cells roughly one to three times the size of neutrophils.  In the dog, skin, lung, gut and liver 
contain the highest number of mast cells. Mast cells derive from CD34 progenitor cells in bone 
marrow (Kirshenbaum et al., 1991; Rottem et al., 1991). Unlike other bone marrow differentiated 
cells, mast cells leave bone marrow as immature cells and mature only after localizing in the 
connective or mucosal tissues (Hatanaka et al., 1979; Kitamura et al., 1979a; Kitamura et al., 
1979b; Hayashi et al., 1985; Kitamura et al., 1985).  Hayashi C, 1985. 
Important characteristic feature of mature mast cells is the presence of cytoplasmic 
granules which contain many biologically active substances, such as histamine, heparin 
chemotactic factors, and cytokines and metabolites of arachidonic acid (Misdorp, 2004). Mast 
cells also release proteolytic enzymes, including collagenase, which may cause collagen lysis; 
lipid mediators, such as prostaglandins, leukotrienes, and platelet activating factors; and cytokines 
(London and Seguin, 2003). Degranulation occurs under the influence of rapid calcium ion influx 
and thus the biologically active substances are released. This confers mast cells an important role 
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in immunological, inflammatory and immediate type allergic reactions (Galli et al., 1999; 
Wedemeyer et al., 2000). Occasionally, both normal as well as neoplastic mast cells show a 
characteristic color change when stained with toluidine blue or Giemsa stain. This metachromasia 
is caused by hexasaccharides, the fundamental unit of heparin (London and Seguin, 2003; 
Misdorp, 2004). 
Mast cell tumors are most common skin tumors in dogs (London and Seguin, 2003; 
Thamm et al., 2006). In dogs, mast cell tumors develop most frequently in skin, but they can also 
grow in the intestine, liver, spleen and elsewhere (Smith et al., 2002).  Dog breeds, such as Boxer, 
Boston terrier, English Bulldog, Labrador retriever, Golden retriever, Cocker spaniel, Schnauzer, 
Shar pei, and Pug are at higher risk for mast cell tumors (Patnaik et al., 1984; Rothwell et al., 
1987). However, all breeds are susceptible and both sexes are equally affected. No gender 
predilection was reported. The mean age for presentation of mast cell tumor is eight years, 
although young puppies have also shown manifestations of this disease. The risk increases with 
increasing age (Welle et al., 2008). 
Mast cell tumors are classified based on histological appearance for staging prognosis. 
World Health Organization classification (Dobson and Scase, 2007) and Patnaik grading (Patnaik 
et al., 1984) of mast cell tumors were widely used. However, recent multicenter research work 
had replaced previous grading system with 2-tier histological grading – low grade and high grade 
(Kiupel et al.).  Cutaneous MCTs are typically solitary lesions, but their clinical appearance can 
be variable, and some dogs can develop more than one apparently unrelated MCT. MCT should 
be considered in the differential diagnosis of any skin tumor. Low-grade, well-differentiated 
MCTs usually present as a solitary, slowly growing dermal nodule. More aggressive MCTs may 
present as large, ill-defined soft tissue masses, and some may be surrounded by satellite nodules 
as the tumor spreads to surrounding lymph nodes. The clinical behavior of MCTs is also variable, 
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ranging from benign to highly malignant. Because of this variable clinical behavior and the 
potential for associated paraneoplastic syndromes, these tumors become difficult to manage. 
The exact etiology of the MCTs is unknown but genetic predisposition and other multiple 
factors are well documented by several researchers (London and Seguin, 2003; Dobson and 
Scase, 2007; Welle et al., 2008). Recently, a stem cell factor receptor - KIT, has been implicated 
in the etiology of canine MCTs (London et al., 1996). C-Kit is activated by ligand-dependent 
tyrosine kinase activity. Activated KIT binds and phosphorylates intracellular substrate proteins, 
initiating a signaling cascade that culminates in a wide array of biologic activities including 
proliferation, migration, maturation, and survival of hematopoietic stem cells, MCs, melanocytes, 
and germ cell lineages (Welle et al., 2008) . In addition to genetic mutations, some authors have 
suggested that chronic inflammation may play a role in MCT development (Govier, 2003).   
 Based on the earlier Patnaik grading system (Patnaik et al., 1984), surgery with wide 
margins is the mainstay of treatment for mast cell tumors for low grade, well differentiated mast 
cell tumors. Surgery and radiation therapy are indicated for the treatment of grade II tumors. 
Chemotherapy is reserved for grade III tumors and incompletely excised grade II tumors (Govier, 
2003; London and Seguin, 2003; Dobson and Scase, 2007). However, based on 2-tier histological 
grading of cutaneous mast cell tumors in dogs (Kiupel et al.), surgery with wide margins or 
surgery coupled with radiation therapy would be indicated whereas chemotherapy is generally 
reserved for high grade mast cell tumors and for incompletely excised low grade mast cell 
tumors. Vinblastine and prednisone combination is chemotherapy of choice to treat mast cell 
tumors. Toceranib phosphate (Palladia
®
), a tyrosine kinase inhibitor was approved by FDA with 
the indications to treat mast cell tumors in dogs. However, treatment of mast cell tumors with 
vinblastine is still considered as standard of care of mast cell tumors in dogs (Robat et al., ; 
Rassnick et al., 2008).  
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8. In vitro studies 
Intrinsic clearance:  
Intrinsic clearance (CLint) is the ability of an organ to remove drug from the blood. The best 
described techniques to predict in vivo pharmacokinetic parameters in humans are from the in 
vivo laboratory animal data using allometric scaling. However, there were some physiological 
differences between humans and animals leading to under or over prediction of human PK 
parameters. Also, increased expenses, issues with animal rights, and time frame for the 
development of drugs in the pharmaceutical research lead to increased interest in the use of in 
vitro studies to predict in vivo pharmacokinetic parameters (Houston, 1994; Obach, 1999c; 
Obach, 1999b; Obach, 2001; Venkatakrishnan et al., 2001; Venkatakrishnan et al., 2003). 
Retrospective analyses of new chemical entities (NCEs) which have entered into clinical 
development shows that approximately 40% of the drugs were discontinued because of 
unacceptable pharmacokinetic parameters (Prentis et al., 1988). In vitro methods became popular 
in the recent years in choosing the potential drug candidate possessing acceptable 
pharmacokinetic parameters, such as optimal clearance to reduce dose, half-life permitting once a 
day oral dose.  Commonly predicted in vivo pharmacokinetic parameters from in vitro data 
include but are not limited to clearance, volume of distribution, elimination half-life, and 
bioavailability.The Common assumptions for in vitro metabolism studies are (Obach, 2011):  
1. Liver is the only organ responsible for metabolism  
2. Cytochrome P450 enzymes are the only enzyme system responsible for metabolism and 
clearance 




4. During acquisition of liver tissues and processing to obtain microsomes, cytochrome 
P450 enzymes remain fully intact 
5. The artificial conditions used to support in vitro metabolism (e.g. Buffers, NADPH) do 
not hamper the rate of metabolism. 
6.  The substrate concentration used in vitro is reflective of that which occurs in the liver in 
vivo and is sub-saturating 
7. The substrate is completely unbound in the incubation mixture 
8. Hepatic transport does not alter clearance 
Commonly used matrices for in vitro drug metabolism studies are microsomes, 
hepatocytes, liver cytosol fractions, liver S9 fractions, liver slices, and heterologously expressed 
cytochrome P450 enzymes.  
Microsomes are commonly used in vitro systems to study drug metabolism. Microsomes 
are vesicle like structures formed from the endoplasmic reticulum when eukaryotic cells are 
subjected to differential centrifugation(Schneider, 1948). Microsomes are rich in phase I enzymes 
including cytochrome P450 enzymes and phase II enzymes, such as UGTs. Microsomes are easy 
to prepare and store at – 80 
0
C without losing potency.  For monoxygenase activity of cytochrome 
P450 enyzmes, NADPH – regenerating system (contains NADP, glucose-6-phosphate, and 
glucose-6-phosphate dehydrogenase) is required to initiate enzyme reaction (Hariparsad et al., 
2006). Pooled liver microsomes are available commercially for different species. There are some 
limitations of microsomes in the drug metabolism studies. Firstly, acidic drugs tend to bind less to 
microsomal proteins whereas basic drugs tend to bind more to microsomes. This will have impact 
in in vitro / in vivo correlations. Secondly, substrates and their metabolites will have ready access 
to enzymes unlike in the real in vivo situation. Thirdly, the concentrations of substrates used in 
the in vitro systems may not reflect the concentrations of drugs in the in vivo system. And lastly, 
several soluble enzyme systems are not present leading to some metabolites not being formed. 
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In classical Michaelis – Menten kinetics, a series of drug concentrations will be incubated in the 
in vitro systems and rate of product or metabolite will be monitored. Theoretical maximum rate of 
reaction, Vmax and Michaelis constant, Km will be determined by plotting substrate concentration 
on x-axis and rate of product formation on y - axis. Km is the value of substrate concentration at 
which rate of reaction is half of theoretical maximum rate of reaction. For new chemical entities 
(NCEs), and for some drugs, product or metabolite may not be identified or standards for 
metabolites may not be available. In such cases, alternative approaches, such as substrate 
depletion approach (Jones and Houston, 2004; Nath and Atkins, 2006) and in vitro half life 
method (Obach, 1999a) are useful to predict Vmax and Km. Regardless of approaches to determine 
the values of Vmax and Km, the equations to calculate intrinsic clearance of drugs are same. Several 
studies have shown methods based on rate of product formation and substrate depletion approach 
are comparable (Stringer et al., 2009). 
In vitro intrinsic clearance of a drug is calculated as a ratio of theoretical maximum rate of 
reaction (Vmax) to Michaelis constant (Km).  
                
    
  
 
The calculated in vitro intrinsic clearance must be scaled up to clearance of drug at the animal 
level using certain scaling factors to obtain in vivo intrinsic clearance (Proctor et al., 2004; Smith 
et al., 2008). The in vivo intrinsic clearance must be combined with other factors, such as fraction 
of unbound drug and hepatic blood flow with some assumptions to determine hepatic clearance 
(Venkatakrishnan et al., 2003).  
                             
                      
          
 
          




There are three commonly used predictive models to predict hepatic clearance, such as well-
stirred model, parallel tube model, and dispersion model (Pang and Rowland, 1977; Roberts and 
Rowland, 1986; Ito and Houston, 2004). 
Well-stirred model: 
 






Where Qh = hepatic blood flow, CLint = in vivo intrinsic clearance,    √         , Rn = 
efficiency number = 
         
  
 , and Dn = dispersion number. 
Of these three models, Well-Stirred model is the simplest with minimal assumptions. However, 
its accuracy was found to be least in several studies. Well-stirred model assumes that liver is a 
single well-stirred compartment and the concentration of unbound drug within the liver is in 
equilibration with unbound drug in the emergent blood (Pang and Rowland, 1977). Parallel tube 
model assumes that liver is composed of series of similar parallel tubes with same concentration 
of enzymes in each cross section. There are other assumptions for all three models, such as 
intimate mixing of blood between hepatic portal blood and the hepatic arterial blood, only 

























































































the blood, the rate of drug elimination is a function of unbound drug. Dispersion model is 
considered to predict hepatic clearance better than other two models. However, the complexity of 
the dispersion model is a limitation and not used frequently.  
9. In vitro / in vivo correlations 
Several studies have shown the utility of in vitro / in vivo correlations in predicting the 
pharmacokinetic parameters. Integrating in vitro metabolism data with limited in vivo studies 
improves the predictive ability of the allometric scaling of pharmacokinetic parameters (Lave et 
al., 1999; NARITOMI et al., 2001; Houston and Galetin, 2003; Venkatakrishnan et al., 2003; 
Poulin et al., 2011). The ability of in vitro methods to predict in vivo pharmacokinetic parameters 
is tested by different ways, such as simple percent accuracy, correlation analyses, and statistical 
methods (average fold error, mean square error, and root mean square error) (Sheiner and Beal, 
1981; Ito and Houston, 2004). Average fold error (afe) is the geometric mean of the ratio of 
predicted and actual values and gives a measure of bias. If the predicted value is equal to actual 
value, then the average fold error would be equal to one. The afe would be equal to 2 if the 
predicted value is within 100% above or 50% below the observed value (Sheiner and Beal, 1981). 
Root mean squared prediction error (rmse) calculates the variance of the predictions from the sum 
of the squares to the prediction errors. Root mean squared prediction error represents precision of 
the assay.  
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(Adapted from Mathijssen, et al., 2007) 
Figure 1. Factors affecting the drug exposure of anticancer drugs 
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Where, G0 = resting phase; G1 = protein synthesis; RNA transcription; S = DNA synthesis; G2 = 
protein synthesis; RNA transcription; M = Mitosis; and G1+S+G2 = Interphase.  





Figure 3. Effect of chemotherapy dose intensity and density on tumor cell kill and regrowth 





Figure 4. Summary of many of the ways of development of drug resistance to chemotherapeutics. 






Figure 5. Illustration of allometric relationship in terms of volume and surface area of cube 
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Figure 10. Chemical structure of desacetylvinblastine (molecular weight: 769) 
 
 















Cisplatin is a platinum containing anticancer drug indicated for the treatment of solid tumors in 
both veterinary and human patients. Cisplatin kinetics has been highly variable among disparate 
patients and difficult to predict.  Current methods of dosing, such as body surface area (BSA) 
based dosing, do not fully standardize drug exposure between patients for most anticancer drugs. 
The purpose of this study was to test whether concomitant consideration of the effects of body 
weight and ontogeny on renal anatomy, physiology, and drug handling would accurately predict 
the clearance of cisplatin and to investigate whether clearance of cisplatin correlates with 
standard allometry or not. Post mortem body weight and organ weights were collected from 364 
dogs (127 juveniles and 237 adults, including 51 geriatric dogs). Renal physiological and 
cisplatin pharmacokinetic studies were conducted in ten male intact dogs including two juvenile 
and eight adult dogs (4-55 kg). Glomerular filtration rate (GFR), effective renal plasma flow 
(ERPF), effective renal blood flow (ERBF), renal cisplatin clearance, and total cisplatin clearance 
were allometrically related to body weight with similar powers of 0.75, 0.59, 0.61, 0.71, and 0.70 
respectively (p<0.05). In contrast to previous studies where cisplatin clearance was poorly 
predicted from GFR, these data showed good correlation between the allometry of kidney weight, 
GFR, renal cisplatin clearance, and total cisplatin clearance. The similar values of these diverse 
mass exponents suggest a common underlying basis for the allometry of kidney size, renal 
physiology, and renal drug handling. 
Introduction 
Cisplatin (cis-Diamminedicholoroplatinum II, cis PtCl2(NH3)2) is a platinum containing 
alkylating - like agent that acts by establishing cross links within and between DNA strands with 
more guanine – guanine intra-strand cross linking (Legendre et al., 2000; Kostova, 2006). 
Cisplatin hydrates with and then forms adducts with purine bases, thus interferes with cell 
division. When the rate of DNA platination exceeds the rate of DNA repair, the cells will enter 
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into apoptosis and die (Bellon et al., 1991; Rabik and Dolan, 2007). Cisplatin was the prototypic 
platinum containing anticancer drug developed among its class of anticancer drugs. Cisplatin is 
primarily indicated for the treatment of solid tumors both in dogs and human patients as a single 
agent or in combination protocols. The aquated forms of cisplatin are highly nephrotoxic (Litterst, 
1981; Rabik and Dolan, 2007; Hanigan et al., 2009) and other toxicities of cisplatin include, but 
are not limited to, peripheral neurotoxicity, ototoxicity, and myelosuppression(Rabik and Dolan, 
2007). Cisplatin has been replaced by carboplatin, a sister analogue of cisplatin, in veterinary 
oncology because of its dose limiting severe nephrotoxicity. However, there is a resurgence of 
interest for cisplatin in veterinary oncology due to its efficacy against solid tumors, such as 
ovarian, testicular, and transitional cell carcinoma (Barabas et al., 2008; McDuffie et al., 2010).  
Cisplatin is continued to treat several solid tumors in human oncology, particularly in pediatric 
oncology, such as testicular tumor, medulloblastoma, neuroblastomas, hepatoblastomas, 
osteosarcomas, and brain tumors.(Fouladi et al., 2008).  
The narrow therapeutic indices of cytotoxic anticancer drugs, such as cisplatin demand 
accurate calculation of doses to optimize drug exposure. The minimum lethal dose of cisplatin in 
dogs is 2.5 mg/kg (≈80 mg/m
2
) (Schaeppi et al., 1973) while the therapeutic dose is 60 – 70 mg/ 
m
2 
(Knapp et al., 1988). Currently, the doses of anticancer drugs are calculated as a function of 
body surface area (BSA) (Pinkel, 1958). There are approximately 400 dog breeds worldwide, 
with156 breeds recognized by American Kennel Club (The Complete Dog Book, AKC 
publication) (http://www.akc.org/breeds/complete_breed_list.cfm).  As there is a wide variation 
in the body sizes of dogs from two pound Chihuahuas to 200 pound Great Dane, current dosing 
methodology based on body surface area had been failing to explain the reported therapeutic 
failure, toxicity, and disposition of several cytotoxic drugs (Page et al., 1988; Arrington et al., 
1994; Gurney, 1996; Frazier and Price, 1998; Price and Frazier, 1998; Ratain, 1998; de Jongh et 
al., 2001; A. Felici et al., 2002; Smorenburg et al., 2003). Several alternative dosing equations 
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were proposed to optimize drug exposure, such as flat fixed dosing, fixed dosing for BSA 
clusters, toxicity adjusted dosing, therapeutic drug monitoring, and retrospective dosing but none 
of them had optimized drug exposure (Gurney, 1996; van Warmerdam, 1997; Warmerdam, 1997; 
Canal et al., 1998a; Canal et al., 1998b; Gao et al., 2004). However, the integration of in vivo data 
with in vitro studies might increase the predictive ability of the resulting pharmacokinetic scaling 
equations (Lave et al., 1999; Houston and Galetin, 2008).  
Unlike some therapeutic drugs, the efficacy of anticancer drugs correlates with drug 
exposure, which is mathematically quantified as area under the plasma concentration versus time 
curve (Moore and Erlichman, 1987; Calvert et al., 1989)  Carboplatin and oxaliplatin are sister 
analogues of cisplatin with reduced nephrotoxicity and their clearance correlates with the 
glomerular filtration unlike cisplatin clearance (Calvert et al., 1989; Peng et al., 1997; de Jongh et 
al., 2001). Prospective pharmacokinetic studies in human patients revealed that glomerular 
filtration rate correlated well with the clearance of carboplatin, resulting in development of a 
dosing equation as a function of creatinine clearance and area under plasma concentration versus 
time curve: Dose (mg) = target area under plasma concentration versus time curve (AUC) x (GFR 
+ 25) (Calvert et al., 1989). Unfortunately, studies in humans have shown that glomerular 
filtration rate does not correlate with the clearance of cisplatin, making it unsuitable to develop 
similar dosing equations for cisplatin as a function of AUC and glomerular filtration rate (Peng et 
al., 1997; de Jongh et al., 2001; Loos et al., 2006). 
Currently, prospective pharmacokinetic studies with toxicity adjusted dosing are 
considered to optimize drug exposure between disparate canine patients. But unfortunately, these 
studies require several in vivo studies which will be expensive and cumbersome. In light of wide 
variation in body sizes of dog breeds, combined with inter individual idiosyncratic responses, a 
better alternative to optimize drug exposure may be to understand the factors that influence the 
clearance of anticancer drugs. If the clearance of a drug is accurately determined, then the dose 
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required to produce desirable drug exposure can be calculated more accurately. As cisplatin is 
excreted through the kidneys, establishing allometric relations between body size and kidney 
weights, renal physiological parameters, and cisplatin pharmacokinetic parameters would 
illustrate how these renal covariates impact the disposition of cisplatin.  
Allometry is the study of non-proportionate relationships between dependent and 
independent variables. With the increase in independent variable, dependent variable also 
increases but with an exponent other than unity.  In simple terms, when the relationship between 
two parameters is not in direct proportion, the relationship is said to be an allometric or non-
proportionate relationship. Mathematically, the dependence of a scalable variable, Y on body 
weight, M is represented by allometric form of equation: Y = aM
b
 where, a = mass coefficient; b 
= mass exponent (West et al., 1997; White and Seymour, 2005; Mahmood, 2007). Many 
anatomical parameters (body surface area, liver weight, kidney weight, and heart weight), 
physiological parameters (basal metabolic rate, glomerular filtration rate, renal blood flow, 
hepatic blood flow, and cardiac output), and important pharmacokinetic parameters (clearance, 
volume of distribution, and elimination half life) are allometrically related with body weight. 
Body size and functional organ mass of important organs, such as kidney and liver, which 
are responsible for metabolism of many drugs, influence the disposition of many anticancer 
drugs. The current literature on organ scaling studies in dogs is limited to few subjects in the 
study or homogenous subjects (Jackson and Cappiello, 1964; Steward et al., 1975; Lutzen et al., 
1976). Pathologists estimate the weight of kidney as 1.13% and 0.4% of body weight in juveniles 
and adults, respectively; heart weight as 0.75% of body weight (Joseph, 1908; Steward et al., 
1975). These estimations might be acceptable in assessing the gross pathology of organs based on 
size to some extent. However, these fixed proportions of body weights may not give accurate 
estimates of organ weights for use in predictive software programs such as physiological based 
63 
 
pharmacokinetic and population pharmacokinetic software programs particularly in species like 
dogs in which there is a wide variation in their body weights.  
 We hypothesize that the concomitant consideration of the effects of signalment, such as 
body weight, gender, and ontogeny on organ physiology and drug handling will accurately 
predict the clearance of anticancer drugs. The rationale for our hypothesis was based on the fact 
that drug clearance depends on functional organ mass and blood flow. (Hanigan et al., 2009; 
Townsend et al., 2009). 
Dogs were declared as laboratory model animals to study pathophysiology and treatment 
of human cancer by National Cancer Institute, Bethesda, MD, USA and the Canine Comparative 
Oncology and Genomics Consortium (CCOGC). The results obtained from these canine species 
can be extrapolated to human beings using interspecies scaling methods (Mahmood, 2007). Most 
of the studies in laboratory animals limit to beagle dogs of 10 kg body weight and extrapolating 
those results to all sizes of dogs result in either under or over dosing of anticancer drugs. Our 
studies are unique in considering different body sizes into account to accommodate their 
functional organ mass, physiology, and pharmacokinetics through allometric relationships. Also, 
this study would give estimates of pharmacokinetic parameters of cisplatin in dogs of different 
body sizes per se. This work would be a step along the continuous efforts to optimize the drug 
exposure in disparate canine patients. 
Materials and methods 
Laboratory supplies: Inulin, para amino hippuric acid, and para amino benzoic acid were 
purchased from Sigma-Aldrich, Inc., St. Louis, MO, USA; all organic solvents were of HPLC 
grade, purchased from Fisher Scientific Inc., Pittsburgh, PA, USA; Vascular access ports were 
purchased from Access Technologies, Skokie, IL, USA; Centrifree
®
 ultrafiltration devices were 
purchased from Millipore, Bedford, MA, USA.  
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Organ weights data collection: Post mortem body weights and organ weights were collected 
from dogs euthanized at Oklahoma City animal shelter, Tulsa animal shelter, and Oklahoma 
Animal Disease Diagnostic Laboratory (OADDL), Stillwater, Oklahoma. Dogs were euthanized 
as a part of a population control program at the shelters; and as patients submitted to OADDL for 
postmortem examination. The data collected from animal shelters was used as training data set 
and the data collected for OADDL was used as validation data set. Dogs above 1 year of age and 
less than 8 years of were considered as the adult group; dogs in the age group of 2 to 5 months 
were considered to be juvenile dogs. There are different opinions about considering a dog as 
geriatric, such as large breeds have shorter life span and attain geriatric phase earlier than small 
breeds (Patronek et al., 1997; Speakman et al., 2003; Galis et al., 2007; Greer et al., 2007). We 
assumed that dogs above 8 years old as geriatric (Cummings et al., 1996a; Cummings et al., 
1996b; Studzinski et al., 2006; Cotman and Head, 2008).  For the estimation of age of dogs, 
patient history and or age based on dentition (Merck veterinary manual) were used. The gender 
and reproductive status (neutered/spayed/intact) of the dogs were noted. Concurrent with the 
collection of kidney weights, heart weights were also collected to see if there is any correlation 
with renal physiological parameters. As cardiac output is dependent on heart weight healthy 
animals, the latter will influence renal blood flow as well.  Body weight and organ weights were 
accurately collected. For the determination of kidney weights, peri-renal fat, capsules, major 
blood vessels supplying the kidneys, and ureters were removed. For the determination of heart 
weight, the heart was cut opened, blood clots were removed and great vessels were trimmed close 
to the base of the heart. A series of a priori inclusion criteria were defined before starting the 
collection of organ weights.  The body condition score (BCS) of dogs was recorded on a scale of 
1 - 9, and dogs with a BCS of 4, 5, and 6 were included in the study (Laflamme, 1997; Parker and 
Freeman, 2011).  Exclusion criteria for dogs euthanized at the shelters included gross 
pathological lesions.  Along with signalment, body weight, and organ weights, tissue specimens 
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were collected from shelter dogs. Histopathology reports were examined for all dogs which were 
collected from OADDL.  
SigmaStat
®
 3.0, SPSS Inc., Chicago, IL was used to analyze the data. The normal 
distribution of the data was tested by Shapiro-Wilk normality test. The training data was log10 
transformed and step wise multiple linear regressions were performed with organ weight as the 
dependent variable and gender, ontogeny, and body weight as independent variables to see which 
individual factors significantly influenced organ weight.  Gender and ontogeny were represented 
as nominal variables with standard denotation: females were denoted as ‘1’ and males were 
denoted as ‘0’; juveniles were denoted as ‘1’ and adults were denoted as ‘0’. Ontogeny is the 
study of development of an individual from embryo to adult. An F-test was used as an indication 
of predictive ability of model. Stepwise multiple linear regression analyses were performed 
separately for juveniles and adults. The slopes of juveniles and adults were tested for differences 
by ANCOVA (SAS 9.2, SAS Institute Inc., Cary, NC, USA).  Outliers were detected by 
Studentized residuals and Cook’s distance. Based on a priori inclusion criteria, data having a 
Studentized residual more than +/- 2 were considered to be outliers. Tissue samples from the dogs 
determined to be outliers were examined histopathologically for evidence of disease. Collinearity 
was tested to see if independent variables have any correlation which might interfere with 
regression analysis. Statistically significant predictors of kidney weight and heart weight were 
retained in the final regression equation. Study significance was set a priori to alpha=0.05. The 
predictive ability of the newly developed allometric equations was validated by comparing to per 
se and validation data set.  The sum of residuals of organ weights predicted with newly developed 
allometric equations and fixed proportions of body weights were compared. Log10 transformed 
residuals of organ weights predicted were plotted against log10 transformed body weights. A 
paired t- test was performed between log10 residual errors and zero to determine the predictability 
of the allometric equations in the validation data set for both organ weights.   
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In vivo animal studies: Ten experimental intact adult male dogs (two juvenile: 8 -12 week old, 
and eight adults: above one year and below three years) were included in the in vivo portion of the 
study.  The body weights of these dogs ranged from 4.25 – 56 kg. Eight dogs were mixed breed 
and two dogs were laboratory beagles. The BCS of dogs were within 4 – 6 out of 10 scale system. 
The Institutional Animal Care and Use Committee approved the husbandry and procedures 
utilized in this study. Separate subcutaneous vascular access ports (VAPs) (Access 
Technologies
®
, Skokie, IL, USA) were implanted in each jugular vein. The length of tubing of 
left side VAP was kept shorter than tubing on right side to ensure that they would not 
communicate in cranial vena cava. The VAPs were maintained using standard procedures for 
aseptic access and heparin lock.  When there were problems in keeping Huber infusion sets in 
place, either long term percutaneous jugular catheters or cephalic catheters were used.  
In vivo renal physiological studies: Dogs were fasted overnight with ad libitum access to water.  
Sterile inulin and para amino huppuric acid (PAH) solutions were prepared and administered as 
intravenous bolus at a dose rate of 58.5 mg/kg and 9.3 mg/kg, respectively. Then, followed by a 
constant rate infusion (CRI) at a dose rate of 50 mg/kg/hr and 18 mg/kg/hr of inulin and PAH, 
respectively, for 180 minutes with a total fluid rate of 8.4 mL/kg/hr (Fischer Patricia A et al., 
2000). Blood samples were collected at 80, 90, 100, 120, and 150 minutes during the infusion and 
hematocrit was determined at each sampling point. Plasma steady state inulin and PAH 
concentrations were determined by a reversed phase high performance liquid chromatography 
using modified previously published papers (Pastore et al., 2001; Meucci et al., 2004). Briefly, 
100 μL of plasma samples were diluted with 100 μL of water. Plasma samples were spiked with 
50 μL of para amino benzoic acid (PABA) as an internal standard. Plasma proteins were 
precipitated with 70% perchloric acid. After centrifugation, the supernatant was transferred into 
disposable borosilicate glass tubes, covered with aluminum foil, and placed into boiling water for 
10 minutes. Five microliters of supernatant were injected onto the high performance liquid 
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chromatography system, using a C18 column (Altech
®
 250 mm x 4.6 mm and 5 μm particle size). 
Separation was achieved with isocratic elution using 87% of 50 mM of sodium phosphate buffer 
(pH: 4.1) and 13% of methanol. Ultraviolet detection was performed at 254 nm. Glomerular 
filtration rate (GFR) was calculated as the ratio of infusion rate of inulin to plasma steady state 
concentration (Cp(ss)) of inulin (Fischer Patricia A et al., 2000).  
             
                               ⁄
            ⁄
⁄  
Similarly, the effective renal plasma flow (ERPF) was calculated as the ratio of infusion rate of 
PAH to steady state plasma concentration of PAH. ERPF was corrected to the extraction ratio 
(ER) of PAH with a value of 0.74 (Chiu et al., 1976; Fischer Patricia A et al., 2000) 
              
                            ⁄
               ⁄
⁄  
Effective renal blood flow (ERBF) was calculated by dividing the value of ERPF with (1 – 
Hct/100 ) (Fischer Patricia A et al., 2000)  
              
                            ⁄
                   ⁄  
⁄  
Where, Hct is the hematocrit determined for each sample collected. These equations were 
primarily derived from the standard equation to calculate clearance as a ratio of infusion rate to 
plasma steady state concentration of a drug (Earle and Berliner, 1946; Shnurr et al., 1980). Renal 
physiological parameters were log10 transformed and regressed against log10 transformed body 
weights (SigmaStat
®
 3.0, SPSS, Chicago, IL).  
Cisplatin pharmacokinetic studies: Dogs were fasted overnight with ad libitum access to fresh 
drinking water. Dogs were housed in metabolic cages beginning 24 hours prior to cisplatin 
administration. Two days prior to and two weeks after performing cisplatin pharmacokinetic 
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studies, complete blood counts and renal biochemistry parameters were tested to confirm that 
values were within normal limits. Dogs were premedicated with ondansetron at a dose rate of 0.3 
mg/kg intravenously to reduce emesis. Cisplatin was administered as a CRI for 20 minutes at a 
dose rate of 1 mg/kg.  Prior to and after administration of cisplatin, dogs were given saline 
diuresis for 5 hours and 2 hours, respectively at a dose rate of 18.3 mL/min/kg. Blood samples 
were collected in heparinized tubes at 0, 10, and 20 minutes during the cisplatin infusion, and at 
5, 15, 30 minutes, and 1, 2, 3, 4, 6, 8, 12, 24, 32, and 48 hours post infusion. As cisplatin is a 
highly protein bound drug, plasma was subjected to ultra-filtration harvested from plasma 




 tubes having molecular 
weight cut off of 30,000 Daltons (Millipore
®
, Bedford, MA) in a fixed angle rotors (Eppendorf
®
 
Centrifuge 5403) and stored at –20
0
 C until analysis. Urine samples (1.2 mL) were collected for 
72 hours and volume of urine voided was recorded at each sampling time point. Metabolic cages 
were washed with 100 mL of water at each sampling time and urine wash samples were collected.  
Elemental platinum concentrations in urine and plasma ultra filtrate samples were quantified by 
using inductively coupled plasma mass spectrometry (ICP-MS) at Utah State Veterinary 
Diagnostic Laboratory, Logan, UT. For all analytical methods, accuracy within 20% of the 
nominal concentration at the lower limit of quantitation (LLOQ) and 15% of the nominal 
concentration at all higher concentrations were set as the acceptable limits. Similarly, an RSD of 
20% at the LLOQ and 15% at higher concentrations were set as the acceptable parameters.  
Compartmental analysis of the data was performed to determine pharmacokinetic parameters with 
models in the format of   ∑    
    
 
   
 using WinNonlin® 5.2 (Pharsight Corp., Mountain 
View, CA). The best compartmental model was chosen using Akaike’s information criteria 
(AIC), co-efficient variation values, and inspection of concentration versus time plots and 
residual plots (Yamaoka et al., 1978). The total and renal clearance of cisplatin values were 
calculated by compartmental and non-compartmental approaches, respectively. The renal 
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clearance of cisplatin was calculated by using the equation: CLrenal  = Xu(72)
 
/ AUC72 where, Xu(72)
 
 
is the total amount of platinum excreted in urine over 72 hour period, AUC72 is the area under the 
plasma platinum concentration versus time curve from time zero to 72 hours (Gibaldi and Perrier, 
1982). The total and renal platinum clearance values were log10 transformed and regressed against 
log10 body weights (SigmaStat
®
 3.0, SPSS Inc., Chicago, IL). 
Results 
Organ scaling: Data were collected from a total of 364 dogs including 237 adult dogs and 127 
juvenile dogs over a period of six years. Based on the a priori inclusion and exclusion criteria, 
237 kidney weight samples and 191 heart weight samples were retained for analysis (Table 1). 
There was no statistical difference between right and left kidney weights (p>0.05), so the weights 
of right and left kidneys were combined to get global kidney weight. Gender was not a significant 
predictor of kidney or heart weights in dogs (p>0.05), whereas body weight and age class 
affected organ weights (p<0.05). Collinearity was not observed among independent variables to 
interfere with regression analysis. There was no difference between the slopes of juveniles and 
adults (p>0.05), so one regression equation was utilized to describe the effect of body weight and 





 (where, adult=0, juvenile=1) R
2
 = 0.93, Sy.x = 0.088 (figure 1); Heart 




(Where, adult=0, juvenile=1) R
2
 = 0.98, Sy.x = 0.057 
(figure 5). Sums of absolute residual errors of organ weights predicted with newly developed 
allometric equations and fixed proportion of body weight approach in training data set per se or 
validation data set were presented in tables 2, 3, 4, and 5. Sums of absolute residual errors of 
kidney and heart weights predicted with the allometric equations in training data set per se and 
validation data set had lower value compared to the fixed proportion of body weight approach.  
Residual plots of log10 transformed residuals of kidney and heart weights of training data set and 
validation data set against body weights were presented in figures 2, 3, 6, and 7. In figures 4 and 
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8, measured organ weights were plotted against body weight in comparison to predicted organ 
weights (allometric and fixed proportion) in validation data sets. The mean log10 residual errors of 
predicted kidney and heart weights with allometric equation in the validation data set were not 
significantly greater than zero (p>0.05). On the other hand, the mean of log10 residual errors of 
predicted kidney and heart weights with fixed proportion of body weight in the validation data set 
were significantly greater than zero and not significantly zero, respectively. However, the p – 
value of allometric residual error was higher than the fixed proportion indicating relative better 
predictive ability. 
In vivo studies 
Renal physiological parameters: One large adult dog (43 kg) was euthanized because of 
unmanageable discospondylitis of lumbar vertebrae. The in vivo data was presented from two 
juvenile and seven adult dogs.  A highly sensitive analytical method was developed to determine 
the concentrations of inulin and PAH simultaneously in canine plasma using a reversed phase 
high performance liquid chromatography. The interday accuracy and precision (relative standard 
deviation) of the assay were within a priori acceptable limits (table 6). The limit of quantitation 
of the assay was 2.5 μg/mL and 3.125 μg/mL for inulin and PAH, respectively. The renal 
physiological parameters of juvenile dogs were not included in the regression analysis. However, 
data was included in the scatter plots to show how their values relate to weight matched adult 
dogs.  The linear regressions of log10 transformed renal physiological parameters against log10 




 = 0.98; 








 = 0.94 (figure 9).  
Cisplatin pharmacokinetics: The accuracy and precision of the assay were within acceptable 
limits (table 7). The limit of quantitation of ICP-MS for platinum concentrations in both ultra 
filtrate and urine was 5 ng/mL. Cisplatin exhibited biphasic elimination. The peak plasma 
concentration of platinum was observed at the end of infusion of cisplatin. The plasma platinum 
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concentrations in small adult dogs had reached below limit of quantitation by 24 hours (figure 
10). The initial plasma half life was short (0.26 ± 0.06 hr) and terminal half life was longer (23.95 
± 9.73 hr). In the compartmental analysis of cisplatin plasma concentrations versus time data, two 
compartmental modeling with 1/y weighting scheme had emerged as the best model fitting 
(figure 10). Best model was chosen based on the model fitting, R
2
 values, co-efficient of variation 
values, Akaike’s information criteria (AIC), and residual plots. The mean pharmacokinetic 
parameters of cisplatin after fitting to two-compartmental model were presented in table 8. 









 = 0.84 (figure 11). There was a good correlation 
between renal physiological parameters and total, and renal platinum clearance (figures 12 and 
13). The cumulative % recovery of platinum in urine was 35.4 ± 4.5 of total dose administered. 
The % cumulative recovery of platinum in urine was higher in smaller individuals compared to 
larger individuals. The total platinum clearance exceeded the renal platinum clearance about 2.7 ± 
0.3 (mean ± SD) fold indicating additional pathways of platinum elimination.  
Discussion 
Organ scaling: In humans and most domestic animals, the variation in adult body weights is 
narrow, limiting allometric effects. Dogs and horses are the two common domesticated animals in 
which a wide range of body weights are noted. Allometric scaling is very useful in extrapolating 
the results from one species to another species through interspecies allometric scaling; and within 
a species, in which a wide variation of body sizes is noted as in dogs and horses through intra-
species allometric scaling (Ritschel et al., 1992; Mahmood, 2007). With the increase in concern 
over live animal studies and ethical issues, computer modeling and simulations with limited data 
from at least one species is gaining more impetus to extrapolate data to other species and within 
the same species. To avoid overlapping of age groups, dogs of 2 – 5 months age were classified 
as juveniles and dogs above one year and less than 8 years were classified as adult dogs. As there 
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are different opinions about defining geriatric status in dogs, dogs above eight years old were 
considered as geriatric dogs in this study.  Both body weight and ontogeny affected kidney and 
heart weight (p<0.05). In contrast to previous studies, gender was not a significant predictor 
(p>0.05) of heart weight (Lutzen et al., 1976; Steel et al., 1976). As reported in previous studies, 
gender was not a significant predictor of kidney  weight  (Prothero, 1984). The canine intra-
species allometric exponents of body weight for kidney and heart weights were 0.79 and 0.86, 
whereas the previously reported interspecies allometric exponents were 0.85 and 0.99, 
respectively (Prothero, 1979; Prothero, 1984). The allometric equations developed in this study to 
predict the organ weights were robust having data from 237 dogs ranging from 0.34 kg to 72 kg 
body weights and representing several breeds. There were few studies describing the allometric 
relationship between organ weights and body weights in dogs. In the previously published 
reports, the data was either collected from a homogenous population or few numbers of subjects 
were included in the study (Jackson and Cappiello, 1964; Deavers et al., 1972; Steward et al., 
1975; Lutzen et al., 1976; Nemec and Vortel, 1981; Korhonen and Harri, 1985). Such data may 
not give better estimates of organ weights. Human and veterinary pathologists estimate kidney 
and heart size as a function of fixed proportion of body weight. Kidney weights are estimated as 
1.13 % and 0.4% of body weight in juvenile  and adult dogs, respectively; Heart weights are 
estimated as 0.75% of body weight (Steward et al., 1975).  The allometric equation developed 
from the training set was used to predict the kidney and heart weights in the training data set per 
se and in the validation data set. The residual plots of both training and validation data sets 
(figures 2, 3, 6, and 7) showed that the residuals of kidney and heart weights determined from 
allometric equations were randomly distributed, in contrast to the residuals of organ weights 
predicted as a fixed proportion of body weights, which had a diagonal and skewed distribution. 
As further support for the greater utility of the allometric approach, the absolute sum of residual 
errors associated with allometric equations were lower than those from the estimates from a fixed 
proportion of body weights (table 2, 3, 4, and 5). Both the lower sum of absolute residual errors, 
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lack of bias in the distribution of residuals, and statistical tests  demonstrate that allometric 
equations to predict kidney weights is better than conventional fixed proportion body weight 
approach. The allometric equations developed in this study can be used in estimating organ 
volume or size for donor and recipient during organ transplantation (Gregory et al., 1987; Phillips 
and Aronson, 2012);  assessing the organ size for toxicological studies(Wolfsegger et al., 2009), 
during post mortem, and surgical procedures; can be incorporated into population based 
pharmacokinetic software programs and physiological based pharmacokinetic software programs. 
These robust and novel allometric equations would replace current allometric equations to predict 
kidney weights. 
Renal physiological parameters: Understanding the renal physiological covariates which might 
correlate with the clearance of cisplatin is important to optimize drug exposure. Creatinine is a 
poor marker of GFR as increased serum creatinine levels occur only with marked damage to 
nephrons making it less sensitive diagnostic marker (Braun et al., 2003; McDuffie et al., 2010).   
Inulin is a non-toxic, inert fructose polysaccharide which is mainly obtained from tubers of 
Dahlia and Chicory, and a dozen of other tubers, roots and artichokes of plants. Inulin is freely 
filtered by glomerular filtration, neither absorbed nor secreted by renal tubules (Brochner-
Mortensen, 1985; Perrone et al., 1990; Prescott et al., 1991). Therefore, the clearance of inulin is 
considered to be the gold standard for the measurement of glomerular filtration rate (Brochner-
Mortensen, 1985; Toto, 1995; Rahn et al., 1999; Finco, 2005).  PAH is an organic anion that is 
freely filtered by glomerulus and extensively secreted into the proximal convoluted tubules and 
very poorly reabsorbed. As PAH is removed from the blood by the kidneys and is nearly removed 
from renal plasma in one passage through the kidney, the renal clearance of PAH is 
approximately equal to effective renal plasma flow (Shnurr et al., 1980; Mann and Kinter, 1993; 
Toto, 1995). During the period of infusion of inulin and PAH as constant rate infusion, plasma 
steady state was achieved within 80 minutes after initiation of administration. In one dog (11.4 
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kg), after receiving loading bolus dose of inulin and PAH, adverse reactions were noticed. Dog 
recovered uneventfully after treatment with dexamethasone and Benadryl; received CRI within 1 
hr of bolus dose. The same dog received constant rate infusion alone to see any difference in the 
values of ERPF with and without receiving bolus dose.  GFR allometrically related with body 
weight with a mass exponent of 0.75 which was very similar to 3/4
th
 power of standard allometry 
(West et al., 1997; White and Seymour, 2005). The 3/4 power is widely accepted as the 
theoretical and experimental interspecific mass exponent relating several allometric relationships 
to body weight (West et al., 1997; Mahmood, 2007). ERPF and ERBF depended on body weight 
with a power of 0.6 which is closer to 2/3
rd
 power of intraspecies scaling. The mass exponents of 
ERPF and ERBF were lower than that of GFR. PAH is transported by organic anion transporters 
(OATs) across proximal convoluted tubules (PCTs). OATs are ATP dependent and reach 
saturation at higher doses of PAH leading to transport maximum of OATs (Tm(PAH)). In previous 
studies, it was shown that with the increase in plasma concentrations of PAH above 30 μg/mL, 
the clearance of PAH had decreased (Mann and Kinter, 1993). In the large dog (55 kg body 
weight), the plasma steady state PAH concentration was 50 μg/mL which was above Tm(PAH). The 
lower allometric exponent of ERPF could be due to the higher doses of PAH in the large dog 
beyond the Tm(PAH) (transport maximum) of the OATs.  The dose of PAH would have been 
adjusted in larger dog without saturating OATs.  
Cisplatin pharmacokinetics: The unbound plasma platinum concentrations in small adult dogs 
(4.25 – 4.7 kg) were below the limit of quantitation by 24 hours after cisplatin infusion, whereas 
the plasma platinum concentrations were above the limit of quantitation until 48 hours in larger 
dogs (10 – 55 kg). The total body clearance of unbound platinum per unit body weight had 
decreased with the increase in body weight. On the other hand, AUC, which is a dose dependent 
parameter, had increased with the increase in body weight (table 7). AUC has been considered as 
one of the important pharmacokinetic parameter as a predictor of therapeutic efficacy and 
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toxicity. There was a 2.8 fold difference in values of AUC between subjects in this study. The 
total body clearance of platinum exceeded renal platinum clearance, suggesting that there are 
nonrenal routes of elimination of cisplatin in conformation with previous studies in different 
species (Reece et al., 1989; Erdlenbruch et al., 2001). Both total body clearance and renal 
clearance of cisplatin were allometrically related to body weight by approximately the ¾ power 
of standard allometry. In contrast to previous studies (Reece et al., 1987; Peng et al., 1997), the 
clearance of cisplatin correlated well with GFR.  The similar allometric powers of total body and 
renal clearance of cisplatin, as well as that of glomerular filtration rate, show cisplatin clearance 
did correlate well with renal markers, including GFR, in the dogs studied. This was a surprising 
finding suggesting that prime doses of cisplatin may follow standard allometry. It may be that 
multiple doses of cisplatin might result in alteration of kidney form and function resulting in a 
different relationship (Aleksunes et al., 2008)(Aleksunes et al., 2008). Some studies have shown 
that multiple doses of cisplatin cause down regulation of molecular biomarkers, organic anion and 
cation transporters responsible for the secretion of cisplatin in the renal tubules (Aleksunes et al., 
2008; Morisaki et al., 2008; McDuffie et al., 2010). Studies involving prime dose and subsequent 
doses of cisplatin are suggested for better understanding about correlation of renal covariates and 
total and renal platinum clearance. 
Conclusions 
The allometric relationship of kidney weights, renal physiological parameters, and cisplatin renal 
and total clearance with body weight suggests a common underlying basis for the allometry of 
kidney form and function. Furthermore, the initial dose of cisplatin follows standard allometry 
and correlates well with GFR in dogs. Pharmacokinetic studies with multiple doses of cisplatin in 
dogs would be needed to determine whether successive doses continue to correlate well with GFR 
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 Training data set Validation data set 
Kidney Heart Kidney Heart 
Juveniles 61 55 16 16 
Adults 106 66 54 54 
Total 167 121 70 70 
Range of body weights (kg) 0.6 – 72 0.5 - 63 
 
Table 1. Number of animals included in the training data set and validation data set for organ 





Table 2.  Sum of absolute residual errors from predictions of kidney weights using the newly 
developed allometric equations and fixed proportion of body weight (1.13 % and 0.4% of body 
weight, respectively for juveniles and adults) in the training data set per se. 
 
 
  Allometric equation Fixed proportion of body weight 
Kidney Juveniles 1.43 5.53 
 Adults 5.75 9.17 
 Total 7.17 14.70 
 
Table 3.  Sum of absolute residual errors from predictions of kidney weights in the validation 
data set using the newly developed allometric equations and fixed proportion of body weight 
(1.13 % and 0.4% of body weight, respectively for juveniles and adults).  
  
Allometric equation Fixed proportion of body weight  
Kidney Juveniles 7.65 12.39 
 
Adults 4.14 8.42 
 
Total 11.79 20.81 
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  Allometric 0.75% of body weight 
Heart Juvenile 2.09 2.99 
 Adult 3.29 3.90 
 Total 5.38 6.88 
 
Table 4. Sum of absolute residual errors from predictions of heart weights, using the newly 
developed allometric equations and fixed proportion of body weight (0.75 % of body weight for 
both juveniles and adults), in the training data set. 
 
 
  Allometric 0.75% of body weight 
Heart Juvenile 0.83 0.62 
 Adult 4.29 5.08 
 Total 5.12 5.70 
 
Table 5. Sum of absolute residual errors from predictions of heart weights, using the newly 
developed allometric equations and fixed proportion of body weight (0.75 % of body weight for 







Analyte Conc. (μg/mL) Accuracy % RSD % 
Inulin 
2.5 88 7 
3.75 93 4 
375 93 4 
750 92 6 
PAH 
3.125 98 9 
5 95 5 
50 90 2 
250 93 3 
 
Table 6. Accuracy and precision of reversed phase high performance liquid chromatography to 
measure the concentrations of inulin and para amino hippuric acid in canine plasma samples. The 
values of accuracy and precision were within acceptable limits. 
 
Pt conc. (ng/mL) Accuracy % RSD % 
5 92 0.4 
325 91 1 
975 107 15 
 
Table 7. Accuracy and precision of ICP-MS method to quantify the concentrations of cisplatin in 







Body weight (kg) 4.25 4.7 10.5 10.9 20.8 23.4 55.4 
K10 (1/hr) 2.4 2.4 1.9 2.2 1.4 0.9 1.1 
Alpha_HL (hr) 0.2 0.2 0.2 0.2 0.3 0.4 0.3 
Beta_HL (hr) 16.4 14.6 19.1 13.5 21.9 49.1 28.5 
Cmax (ng/mL) 1023.0 1391.7 1754.4 1699 963.2 663.6 1654.9 
Vss (mL/kg) 6847.6 3841.4 4772.0 3434 9453.6 25167.7 6845.8 
CL (mL/hr/kg) 899.5 701.7 451.0 509 628.4 682.9 285.7 
AUC (hr*ng/mL) 722.6 926.3 1441.2 1276 1034.4 951.8 2275.0 
 
Values are expressed as the mean ± SD. K10 = elimination rate constant; Alpha_HL = 
distribution half - life; Beta_HL = elimination half - life; Vd(ss) = apparent volume of distribution 
at steady state; CL = total body clearance; AUC = area under the serum drug concentration-time 
curve, extrapolated to infinity.  
Table 8. Mean pharmacokinetic parameters for platinum after IV administration of 1 mg/kg of 








Figure 1: Scatter plot of kidney weight (g) against body weight (kg) from 61 juvenile and 106 
adult dogs. The kidney weight allometrically related to body weight and ontogeny as: Kidney 




 where, adult = 0, juvenile = 1, R
2
 = 0.93 (p <0.05).  
 
Kidney weight (g) = 9.35 BW0.789 100.095 x ontogeny 
























Figure 2. The residuals of log10 transformed kidney weights predicted with the newly developed 
allometric equation and fixed proportion of body weights were plotted against log10 transformed 
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Figure 3. The residuals of log10 transformed kidney weights predicted in validation data set with 
the newly developed allometric equation and the fixed proportion of body weights were plotted 
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Figure 4: Scatter plots of measured kidney weight (g) against body weight (kg) of validation data 
set. The solid line indicates the predicted kidney weights using the newly developed allometric 
equation. The dashed line indicates predicted kidney weights using 1.13% and 0.4% of body 
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Figure 5: Scatter plot of log10 heart weight (g) against log10 body weight (kg) from 121 juvenile 
and adult dogs of training data set. The heart weight allometrically related to body weight and 











Heart weight (g) = 10.86 BW0.86 10-0.095xontogeny 





















Figure 6. The residuals of log10 transformed heart weights predicted with the newly developed 
allometric equation and 0.75% of body weights were plotted against body weights in the training 
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Figure 7. The residuals of log10 transformed heart weights predicted with the newly developed 
allometric equation and 0.75% of body weights were plotted against body weights in the 
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Figure 8: Scatter plots of measured heart weight (g) against body weight (kg) of validation data 
set.  The solid line indicates the predicted heart weights using newly developed allometric 
equation with training data set. The dashed line indicates predicted heart weights using 0.75% 
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Figure 9: Log10 transformed renal physiological parameters were regressed against log10 
transformed adult body weights 
 
GFR = 0.5 BW0.75 
R² = 0.98 
ERBF = 3.4 BW0.61 
R² = 0.94 
ERPF=2.3BW0.59 
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Figure 10: Two-compartmental model fitting of platinum concentrations in a large sized (55 kg) 
and small sized adult dogs (4.2 kg). Circles indicate observed concentrations and black dots 
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Figure 11: Relationship between total and renal platinum clearance, and body weight 
 
CLrenal = 0.35 BW
0.77  
R² = 0.84 
CLtotal = 1.08 BW
0.72  
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Figure 12: Correlation between total platinum clearance and renal physiological parameters 
 





































R² = 0.8754 
R² = 0.8931 







































Vinblastine and prednisone regimens are well tolerated by dogs with mast cell tumors but their 
efficacy is less than 50% of treated dogs indicating under-dosing with the current body surface 
area based dosing. We hypothesize that novel dosing equations that relate the pharmacokinetics 
of vinblastine to liver weight and drug metabolizing activity will yield more predictable plasma 
drug levels than current dosing formulae. Liver and body weights were collected from a total of 
324 dogs and multiple linear regressions were performed.  Microsomes were purified by 
differential centrifugation in twenty three liver samples. The density of cytochrome P450 
enzymes in the microsomal samples was determined by ascorbate reduced dithionate difference 
spectra. The intrinsic clearance (CLint) of vinblastine (0.025 – 61.65 μM) was determined by 
substrate depletion approach. The hepatic clearance (CLhep) of vinblastine was predicted by well-
stirred, parallel tube, and dispersion models.  In order to compare in vitro metabolism studies, in 
vivo vinblastine pharmacokinetic studies were conducted in four adult male dogs (10 - 54 kg). A 
novel dosing equation was developed to calculate the doses of vinblastine as a function of 
clearance and area under plasma concentration versus time curve.  Liver weight, density of 
cytochrome P450 enzymes, intrinsic clearance, and hepatic clearance of vinblastine were 
allometrically related to body weight. All three predictive models predicted CLhep within 
acceptable limits. A novel dosing equation was developed: Dose = AUC*(21.6 BW
0.78
) and shown 
that current doses are suboptimal.  These are proof-of-concept studies and have to be tested in a 
large sample size for definitive results. 
Introduction 
Vinblastine is a vinca alkaloid isolated from the periwinkle plant, Catharanthus rosesus. 
Vinblastine is indicated for the treatment of several soft tissue tumors in both human and 
veterinary patients. Mast cell tumors are one of the most common cutaneous tumors in dogs of all 
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ages and breeds. However, mast cell tumors are more prevalent in geriatric dogs and some breeds, 
such as Boston terriers, Pugs, Boxers, and Labrador retrievers. Mast cell tumors are staged into 
different categories by different classification systems, such as World Health Organization 
(WHO) (Dobson and Scase, 2007), Patnaik grading (Patnaik et al., 1984), and 2 – tier grading 
system (Kiupel et al.). However, recent 2 – tier grading system of cutaneous mast cell tumors had 
replaced previous grading systems. Surgical excision with wide margins remains the mainstay of 
treatment for resectable mast cell tumors (Welle et al., 2008). In advanced stages, surgical 
excision or radiation therapy may be coupled with chemotherapy. Vinblastine combined with 
prednisone regimens are well tolerated but are effective in less than 50% of treated dogs (Thamm 
et al., 1999; Rassnick et al., 2008). Oral toceranib phosphate (Palladia®) is the only FDA 
approved drug with an indication to treat mast cell tumors in dogs. However, vinca alkaloid and 
prednisone regimens are still considered a standard of care for the treatment of certain 
presentations of mast cell tumors in dogs. Therapeutic efficacy of vinblastine and toceranib 
combinations were investigated in dogs with mast cell tumors (Robat et al.).   
Currently, vinblastine exposure is normalized by calculation of the dose rate as a direct 
proportion of body surface area. However, few pharmacokinetic studies of vinblastine have been 
performed in dogs, and the ability of dosing on the basis of BSA to normalize drug exposure in 
disparate phenotypes of dogs is currently unknown (Creasey et al., 1975; de Lannoy et al., 1994). 
There are approximately 400 breeds of dogs worldwide and 156 are recognized by the American 
Kennel Club. Unlike many species, dogs exhibit wide variation in body weights, ranging from a 1 
kg Chihuahua to a 100 kg pound Saint Bernard. Despite such profound variability, most of the 
pharmacokinetic studies are limited to one breed or size, such as beagle dogs as the model 
laboratory animal for this species.  Results from such studies may be insufficient to determine 
whether drug exposure is normalized among disparate canine patients. The low risk for adverse 
effects and low therapeutic outcome with vinblastine / prednisone regimens suggest that most 
dogs may be receiving suboptimal doses of vinblastine. Therefore, the therapeutic outcome of 
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vinblastine and prednisone regimens may be improved if the vinblastine doses were optimized to 
produce drug exposure that was as similar as possible among different patients. The efficacy of 
anticancer drugs is correlated with the drug exposure unlike many therapeutic drugs (Moore and 
Erlichman, 1987; Calvert et al., 1989; van den Bongard et al., 2000). Mathematically, drug 
exposure is calculated as AUC (area under plasma concentration versus time curve) (Hempel and 
Boos, 2007).   The doses of anticancer drugs are calculated as function of clearance and drug 
exposure, dose = AUC * clearance. Thus, to achieve a constant drug exposure in disparate 
patients, clearance is the important pharmacokinetic parameter. If the total body clearance of a 
drug is determined accurately, then the dose required to produce therapeutically relevant drug 
exposure can be calculated accurately.  
We hypothesize that novel dosing equations that relate the pharmacokinetics of 
vinblastine to liver weight and drug metabolizing activity will yield more predictable plasma drug 
levels than current dosing formulae. The rationale for our studies was based on: vinblastine is 
primarily metabolized in the liver through oxidation reaction of phase I and excreted mostly in 
bile through feces and to some extent renal secretion. For xenobiotics that are cleared by the liver, 
the intrinsic hepatic clearance (CLint) depends on drug metabolizing activity, the density of 
enzymes per volume of liver, and liver mass relative to body weight.  
The success rate of drug development would be improved with decreased expenses if 
there are better in vitro approaches to predict in vivo pharmacokinetic parameters. Approximately 
10% of the drug candidates that are selected for clinical development are marketed and out of 
those marketed, approximately 40% are discontinued because of unacceptable pharmacokinetic / 
toxicokinetic properties (Prentis et al., 1988; Obach et al., 1997). To decrease expenditures in 
drug development, the best approach would be to perform in vitro / in vivo correlation studies to 
test the suitability of in vitro studies to predict in vivo pharmacokinetic parameters. Because of 
the short amount of time it takes, less expenses, and easy applicability to in vivo pharmacokinetic 
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parameters, in vitro studies are becoming more popular in the preclinical screening of new 
chemical entities (NCEs) and to make go or no-go decisions in early drug discovery phases.  
Physiologically based pharmacokinetics (PBPK) modeling and allometric scaling are the 
two common approaches to predict in vivo pharmacokinetic parameters from in vitro data. PBPK 
modeling is complex and requires lot of information, software programming, and expertise. On 
the other hand, allometric scaling is simple to use, requires minimal data, and less expertise to 
perform. Allometric scaling is particularly important in extrapolating results from one species to 
another species (interspecies allometric scaling) and within a species where there is a wide 
variation in body weights, in species, such as dogs and horses (intraspecies allometric scaling). 
However, PBPK modeling is a highly versatile and powerful tool in predicting absorption, 
distribution, metabolism, and excretion of a chemical compound or drug. In order to perform 
PBPK modeling to predict the disposition of a drug, accurate input of information on anatomical, 
physiological, and preliminary estimates of pharmacokinetic parameters are needed. 
Unfortunately, such information is available in the literature only for laboratory beagle sized dogs 
that may not predict required information for wide range of canine breeds. 
Many anatomical (BSA, liver weight, kidney weight, and other organs), physiological 
(basal metabolic rate, glomerular filtration rate, renal blood flow, hepatic blood flow, and cardiac 
output), and pharmacokinetic parameters (clearance, volume of distribution, and elimination half-
life) vary with body size in a disproportionate relationship which can be mathematically 
represented as y = aW
b
, where ‘y’ is the dependent parameter, ‘a’ is the mass coefficient, ‘W’ is 
body weight, and ‘b’ is the mass exponent or power. Pharmacokinetic scaling has consistently 
revealed the inadequacy of any fixed mass exponent, such as 2/3 or ¾ powers, in predicting drug 
pharmacokinetic parameters as a function of body weight. Allometric or non-proportional 
relationships between body size and drug clearance are magnified when body weight varies 
widely. The effect of body weight on drug clearance is particularly important in dogs, where there 
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is wide range in body weights. Therefore, the accuracy of pharmacokinetic scaling can only be 
judged retrospectively and requires the construction of individual scaling relationships for each 
particular drug, based on multiple in vivo studies. Conducting such in vivo studies is not only 
expensive but also cumbersome. However, the integration of in vivo allometric considerations 
with in vitro studies increases the predictive power of the resulting equations. Once the true 
influence of individual factors such as, body weight, gender, and ontogeny are understood, drug 
doses can be individualized as a function of significant individual factors and in combination with 
other individual characteristics, such as disease status. 
The current studies on organ scaling are limited to few subjects and homogenous 
population (Jackson and Cappiello, 1964; Steward et al., 1975; Lutzen et al., 1976). Pathologists 
estimate the weight of liver as 3.5% of body weight (Steward et al., 1975). However, these fixed 
proportions of body weights may not give good estimates of liver weights in dogs as there is wide 
variation in body weights. 
The overall objective of this study was to develop novel dosing equations to accurately 
predict the dosages of vinca alkaloids in dogs and to establish in vitro / in vivo correlations of 
hepatic clearance of vinblastine in dogs. 
Materials and methods 
Materials: Vinblastine sulfate, dithionate, ascorbic acid were obtained from Sigma Aldrich Inc., 
St. Louis, MO, USA. Vindesine sulfate was obtained from LKT laboratories, Inc., St. Paul, MN, 
USA. Nicotinamide adenine dinucleotide phosphate - regenerating system (NADPH-RS) 
consisting of solution A (glucose-6-phosphate and nicotinamide adenine dinucleotide phosphate) 
and solution B (glucose-6-phosphate dehydrogenase) were purchased from BD Biosciences, San 
Jose, CA, USA. HPLC grade organic solvents and reagents were purchased from Fisher 
scientific, Pittsburgh, PA, USA. 
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Allometric scaling of liver weights: Post mortem body weights and liver weights were collected 
from dogs euthanized at the nearby urban animal shelters for population control and from 
submissions to the Oklahoma animal disease diagnostic laboratory (OADDL), Stillwater, 
Oklahoma for post mortem examination. Dogs above 1 year of age and less than 8 years of old 
were considered as adult group; dogs in the age group of 2 to 5 months age were considered as 
juvenile dogs. There are different opinions about considering a dog as geriatric, such as large 
breeds have shorter life span and attain geriatric phase earlier than small breeds (Patronek et al., 
1997; Speakman et al., 2003; Galis et al., 2007). We assumed that dogs above 8 years old as 
geriatric (Cummings et al., 1996a; Cummings et al., 1996b; Studzinski et al., 2006; Cotman and 
Head, 2008).  For the determination of age of dogs, patient history and or dentition (Merck 
veterinary manual) were used. The gender and reproductive status (neutered/spayed/intact) of the 
dogs were noted. For the determination of liver weights, gall bladder was cut opened, drained, 
and retained. Data were collected from a total of 364 dogs including 237 adult dogs and 127 
juvenile dogs over a period of six years. A series of a priori inclusion criteria were defined before 
starting the collection of organ weights and data outside these criteria were omitted at the stage of 
data collection.  The body condition score (BCS) of dogs was recorded on a scale of 1 – 9 
(Laflamme, 1997; Parker and Freeman, 2011).  Dogs with BCS of 4, 5, and 6 were included in 
the study.  Tissue specimens were also collected along with the signalment of dogs for the 
collected from animal shelters. Histopathology reports were examined for all dogs which were 
collected from OADDL.  
For the statistical analysis of the data, SigmaStat
®
 3.0, SPSS, Inc., Chicago, IL, USA and 
SAS 9.2, SAS Institute Inc., Cary, NC, USA were used. The normal distribution of the data was 
tested by Shapiro-Wilk normality test. Outliers were detected by Studentized residuals and 
Cook’s distance. Based on a priori inclusion criteria, dogs having Studentized residual more than 
+/- 2 were considered as residuals. Residuals outside the inclusion criteria were removed and 
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analyzed again to detect outliers and the resulting outliers were examined histopathologically to 
consider inclusion in the model. Data were log10 transformed and step wise multiple linear 
regressions were performed with liver weight as dependent variable and gender, age class, and 
body weight as independent variables to see which individual factors influenced the organ weight.  
Gender and ontogeny were represented as nominal variables with standard denotation: females 
were denoted as ‘1’ and males were denoted as ‘0’; juveniles were denoted as ‘1’ and adults were 
denoted as ‘0’. F-test was used as an indication of predictive ability of model. Stepwise multiple 
linear regression analyses were performed separately for each group of juveniles and adults. 
Statistical significant predictors of liver weight were retained for the analysis. The statistical 
significant difference between the slopes of juveniles and adults was determined using ANCOVA 
(SAS 9.1, SAS Institute Inc., Cary, NC, USA).  Collinearity was tested to see if independent 
variables have any correlation which might interfere with regression analysis. Study significance 
was set a priori to alpha=0.05. The data collected from animal shelters was used as training data 
set to perform multiple linear regression analysis and develop allometric equation. The data from 
the OADDL was used as validation data set to verify the resulting regression equations of shelter 
data. The predictive ability of the newly developed allometric equations was validated by 
comparing to training data set per se and validation data set.  The sum of residuals of organ 
weights predicted with newly developed allometric equations and fixed proportions of body 
weights were compared. Log10 transformed residuals of organ weights predicted were 
plotted against log10 transformed body weights. A paired t- test was performed between 
log10 residual errors and zero to determine the predictability of the allometric equations in 
both training and validation data sets.   
Microsomal purification: Liver samples were collected from twenty three adult dogs (2.3 - 54 
kg) euthanized at the Oklahoma City Animal Shelter, Oklahoma City, OK within thirty minutes 
after euthanasia. Samples were plunged in ice cold Lactated Ringer’s solution. Any apparent 
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vessels or bile ducts were flushed thoroughly with saline until sample became blanched. Samples 
were carried to the laboratory for microsomal purification either on ice or in liquid nitrogen. 
Microsomes were purified based on the standard procedure (Schneider, 1948). Approximately, 25 
- 35 g of liver sample was finely chopped into small pieces with a scalpel blade. Using a clean 
scissors, any visible connective tissue was trimmed. Minced liver sample was transferred to 
Potter-Elvehjem homogenizer and homogenized with three volumes of homogenization buffer. 
The homogenate was centrifuged at 10,500 rpm for 20 minutes at 4 
0
C. The fatty layer from the 
supernatant was removed, which is the S9 fraction. Supernatant was transferred into cold 
ultracentrifuge tubes (16 – 26 mL) and centrifuged at 35,000 rpm for 65 minutes at 4 
0
C using 
55.2 Ti rotor. Supernatant was poured off and an equal amount of (16 – 26 mL) ice cold 
homogenizing buffer was added.  Pellet was resuspended and transferred to 30 mL homogenizer 
for gentle homogenization. The homogenate was centrifuged at 35,000 rpm for 65 minutes at 4 
0
C. Supernatant was poured off and microsomes were resuspended in storage solution. Pellets 
were homogenized in 15 mL homogenizer and microsomes were stored until use, at -80 
0
C. 
 Microsomal protein determination: The protein concentration microsomal samples was 
determined by Bradford protein assay in triplicate using Bio-Rad Protein Assay Kit, Hercules, 
CA (Bradford, 1976).   
Cytochrome P450 density: The density of cytochrome P450 in microsomes was determined by 
ascorbate reduced dithionate - difference spectra (Matsubara et al., 1976; Johannesen and 
DePierre, 1978), a modified method of gold standard method (Omura and Sato, 1964a; Omura 
and Sato, 1964b) in duplicate using a Cary 300 UV – vis spectrophotometer. In brief, samples 
were diluted 1:10 with cytochrome P450 dilution buffer (100 mM sodium phosphate buffer, pH 
7.4). Baseline was run with buffer from 400 to 500 nm. Ten microliters of ascorbic acid was 
added to microsomes to make final concentration of 250 µM and the baseline was recorded. Then 
carbon monoxide (CO) was bubbled into the microsomal suspension for about 1 minute and 
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spectrum was obtained.  Few grains of sodium dithionate were added to the microsomal 
suspension in the cuvette. Then contents were mixed well and the spectrum was obtained after 2 
minutes. The concentration of cytochrome P450 was determined from the spectrum using Beer’s 




 for the difference of absorption 
between peak position at 450 nm and 490 nm.  
In vitro incubations: The conditions for microsomal incubation of vinblastine, such as range of 
vinblastine concentrations for incubations, microsomal protein concentration, incubation 
temperature, time of pre-incubation and incubation, and stop solution to be used were optimized. 
All microsomal incubations were done in duplicate. Vinblastine sulfate (in methanol) was added 
to microsomal samples which were diluted to 0.5 mg/mL microsomal protein concentration with 
100 mM sodium phosphate buffer (pH 7.4) in the final concentrations of 0.025 - 61.65 μM (final 
organic solvent concentration of 1%). Fortified microsomal samples were pre-incubated for 3 
minutes at 37 
0
C in a shaking water incubation bath with open lid. Reaction was initiated by 
addition of NADPH - RS at the final concentration of 1.55 mM. Reactions were stopped by 
addition of 400 μL of ice cold acetonitrile containing internal standard, vindesine sulfate to 200 
μL of microsomal incubate samples at  pre, 3, 5, 10, 15, 20, and 30 minutes.  Samples were 
vortex mixed and centrifuged at 10,000 g at room temperature for 10 minutes (Biofuge, Pico, 
Heraeus and Sorvall Company, Germany). To 200 μL of supernatant, 400 μL of 80 mM 
ammonium acetate (pH: 2.5) was added and vortex mixed. The concentrations of vinblastine in 
the microsomal incubate samples were determined by reversed phase high performance liquid 
chromatography (RP-HPLC). The Waters
® 
RP - HPLC consisted of 1500 series binary pump, 
column heater set at 30 
0
C, in-flow degasser, 717 auto sampler set at 4 
0
C, and fluorescence 
detector at excitation wavelength of 254 nm and emission wavelength of 320 nm. Fifty micro 
liters of samples were injected onto C18 (250 mm x 4.6 mm and 5 μm particle size) column and 
separated under isocratic elution with mobile consisting of 53% of 80 mM ammonium acetate 
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(pH: 2.5) and 47% of acetonitrile and methanol (1:1). For all analytical methods, accuracy within 
20% of nominal concentrations at the lower limit of quantitation (LLOQ) and 15% of the nominal 
concentrations at higher concentrations; similarly, an RSD of 20% at the LLOQ and 15% at 
higher concentrations were set as the acceptable limits.  
The data was analyzed on WinNonlin
®
 5.2 pharmacokinetic software program (Pharsight 
Corp., Mountain View, CA) using pharmacodynamic model # 101:     
      
       
 ) to obtain the 
values of theoretical maximum rate of reaction (Vmax) and Michaelis constant (Km). In vitro 
intrinsic clearance of vinblastine was calculated as a ratio of Vmax to Km                  
    
  
  . 
The values of in vitro intrinsic clearance were scaled to the whole animal using a scaling factor of 
55 mg microsomal protein/g of liver to get in vivo intrinsic clearance of vinblastine: 
(                             
                      
          
 
          
                
 )  (Smith et al., 
2008; Obach, 2011). Hepatic clearance of vinblastine was predicted using three predictive 
models, such as well stirred model, parallel tube model (undistributed sinusoidal model), and 
dispersion model (Pang and Rowland, 1977; Houston and Carlile, 1997).  
 
Well stirred model (equation 1):   
 
Parallel tube model (equation 2): 
 


























































































Where, fu = fraction of unbound drug; Qh = hepatic blood flow = 29.06 mL/min/kg hepatic blood 
flow was used (Hanna, 1984); a = (1+4RnDn)
1/2
 ; Rn= fu x Clint /Qh  ; Dn = dispersion number = 
0.17. 
In vivo vinblastine pharmacokinetic studies: In order to compare hepatic clearance of 
vinblastine determined in the in vitro vinblastine metabolism studies, in vivo vinblastine 
pharmacokinetic studies were conducted in four adult male dogs (10 – 54 kg). All dogs had BCS 
of 4 – 6. Two small dogs (10 kg) were laboratory beagles and two dogs (43-54 kg) were mixed 
breeds. The Institutional Animal Care and Use Committee approved the husbandry and 
procedures utilized in this study.  Indwelling vascular access ports (VAP) (Access Technologies
®
, 
Skokie, IL, USA) were implanted in jugular veins under anesthesia following standard procedures 
(Bagley, 1990; Henry et al., 2002; Cahalane et al., 2007). The Huber infusion sets (Access 
Technologies
®
, Skokie, IL, USA) were used to access ports to administration of drug and 
collection of blood samples. The VAPs were maintained using standard aseptic procedures for 
access and heparin lock. Dogs were kept in metabolic cages and fasted overnight with ad libitum 
access to water. Vinblastine sulfate (1 mg/mL) (APP Pharmaceuticals LLC, Schaumburg, IL, 
USA) was administered as a bolus dose at the rate of 0.075 mg/kg. Blood samples were collected 
at pre, 2 min, 5, 10, 15, 20, 30, 45 min, 1 hr, 2, 3, 4, 5, 6, 9, 12, and 24 hr post infusion. Urine 
samples were collected at 1hr, 3, 5, 7, 12, 24, 32, 48, 56, and 72 hr post infusion. Metabolic cages 
were washed with 100 mL of nanopure water to get wash sample at each urine sample collection 
time point. An analytical method was developed to quantify the concentrations of vinblastine and 
desacetylvinblastine (DVLB), a metabolite of vinblastine, in urine and plasma samples using 
liquid chromatography/atmospheric pressure chemical ionization – tandem mass spectrometry 
(LC/APCI-MS/MS). The system consisted of a Schimadzu HPLC system (Shimadzu corporation, 
Kyoto, Japan) having a system controller (CBM-20A), binary solvent delivery unit (LC-20AD), 





and a column oven set at 40 
0
C (CTO-20AC) with a Restek Allure Pentafluorophenyl (PFP) 
Propyl 5 μm 50 x 2.1 mm column (Restek, Bellefonte, PA), and guard cartridge (Restek 5 μm, 
Ultra Biphenyl, 10 x 2.1 mm) were used. An Applied Biosystems 4000 Q-Trap MS/MS system 
(Applied Biosystems, Foster City, CA) equipped with an atmospheric pressure chemical 
ionization source and a NitroGen N300DR nitrogen generator was used (Peak Scientific 
Instruments Ltd, Paisley, United Kingdom). Analyst
®
 1.5 software for Windows
®
 was used to 
acquire and analyze the data.   
Plasma and urine samples were processed on Oasis
®
 HLB solid phase extraction 
cartridges (Waters
®
, MA). Briefly, for calibrants and quality controls, 480 μL of blank plasma or 
urine were added to micro-centrifuge tubes. Ten microliters of vinblastine and 10 μL of 
desacetylvinblastine calibrator solutions in methanol were added to achieve final concentrations 
of 0.125 - 100 ng/mL and 1 – 2,000 ng/mL in plasma; 0.125 - 5 ng/mL and 0.5 - 100 ng/mL in 
urine samples, respectively. Incurred samples of in vivo vinblastine pharmacokinetic study  were 
thawed at room temperature and 500 μL of sample matrix were added to the labeled micro 
centrifuge tubes. All samples were diluted with 500 μL of water containing 10 μL of 500 ng/mL 
vinorelbine and vortex mixed. Oasis
®
 HLB cartridges were preconditioned with 1 mL of 
methanol and 1 mL of water. Samples were loaded onto the column slowly, at a rate of 
approximately 1 – 2 drops per second. Cartridges were washed with 2 mL of water, and then 
dried at maximum airflow for 30 minutes. Samples were slowly eluted with 2 mL of methanol 
into labeled silanized glass tubes. The eluted samples were dried under nitrogen at 30 0C and 
were resuspended in 150 μL of buffer, containing 50% 5 mM ammonium acetate, 25% 
acetonitrile, and 25% methanol. For plasma samples, 100 μL of the redissolved sample was 
injected onto the system, whereas 20 μL were injected for urine samples.  Silanized glassware 
was used wherever possible during sample preparation to avoid systemic under-estimation of 
analyte concentration and to increase sensitivity (Trim et al., 2008; Damen et al., 2009; Damen et 
114 
 
al., 2010). The mobile phase consisted of 10% 5 mM ammonium acetate buffer, adjusted to a pH 
of 3.5 with glacial acetic acid, and 90% HPLC grade methanol. Separation was achieved by 
isocratic elution at a flow rate of 0.75 mL/min.  
Pharmacokinetic parameters were calculated by compartmental analysis with the models 
of the form,   ∑    
    
 
   
 on WinNonlin
®
 5.2 pharmacokinetic software program (Pharsight 
Corp., Mountain View, CA) using pharmacokinetic model # 18. The appropriate compartment 
model was chosen based on Akaike’s information criteria (AIC), co-efficient of variation values, 
and inspection of concentration versus time plots and residual plots (Yamaoka et al., 1978). The 
renal clearance of vinblastine was calculated using the equation: CLrenal = X0-72 /AUC0-72 , where 
AUC0-72 is the area under plasma concentration versus time curve from 0 – 72 hr and X0-72 is the 
total amount of drug excreted in the urine from time 0 – 72 hr. Hepatic clearance of vinblastine 
was determined by subtracting renal clearance from the total clearance of vinblastine. The total 
and hepatic clearance of vinblastine was regressed against body weights (SigmaStat
®
 3.0, SPSS 
Inc., Chicago, IL). 
In vitro/in vivo correlations: The values of hepatic clearance of vinblastine obtained in in vitro 
and in vivo studies were compared to see the utility of in vitro studies in predicting the in vivo 
pharmacokinetic parameters of vinblastine in dogs. The percent accuracy was calculated for each 
predictive model.  The accuracy of predictions of hepatic clearance with these predictive models 
was tested by percent accuracy,  root mean squared error (rmse), and the average fold-error (afe) 
which reflects precision and bias, respectively (Sheiner and Beal, 1981). The correlation analyses 
were also performed between the observed and predicted hepatic clearance values. 
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Results 
Organ scaling: The organ weights data had passed normality test. There was no difference 
between the slopes of juveniles and adults per ANCOVA results (SAS 9.2, SAS Institute Inc., 
Cary, NC, USA). The data was combined and multiple linear regression analysis was done for the 
combined data. Gender was not a predictor of liver weight (p>0.05) but body weight and 
ontogeny had significantly influenced the liver weight (p < 0.001). A regression equation was 
developed from data collected from the training data set, a total of 160 dogs (58 juveniles and 102 
adults) (figure 1). Using the newly developed allometric equation, weight of the liver for a given 







=0.93, Sy.x = 0.094, Where, for ontogeny, adult =0 and juvenile =1. The allometric 
equation developed from the training data set was validated in the training data set per se and 
validation data set. Log10 transformed residuals of liver weights were plotted against body 
weights in both training and validation data set were presented in figures 2 and 3. Sums of 
absolute residual errors of predicted liver weights with newly developed allometric equation were 
lower compared to fixed proportion of body weights (tables 1 and 2). The mean of log10 residual 
errors of predicted liver weights with allometric equation in training and validation data sets were 
not significantly different from zero and significantly different from zero, respectively. In figure 
4, measured liver weight was plotted against body weights on logarithmic coordinates in 
comparison with predicted liver weights with the newly developed allometric equation and 3.5% 
of fixed proportion of body weights. The average proportion of liver weight to body weight in 





In vitro studies: 
Microsomal purification was done successfully with differential centrifugation method 
(Schneider, 1948). The concentrations of microsomal protein were in the range of 12.35 mg/mL 
to 36 mg/mL.  
Cytochrome P450 density: the density of cytochrome P450 enzymes in the hepatic microsomes 
was determined by gold standard method, carbon monoxide difference spectrum. Microsomal 
samples which were processed from frozen liver samples had hemoglobin contamination and 
such samples had a prominent peak at 420 nm while obscuring the peak at 450 nm. In order to 
reduce the peak at 420 nm without affecting the peak at 450 nm, different methods were tested, 
such as dithionate difference spectra, ascorbate reduced dithionate difference spectra, and 
ascorbate and PES reduced dithionate difference spectra (figures 5, 6, 7, and 8). Out of these four 
methods, ascorbate reduced dithionate difference spectra and carbon monoxide difference spectra 
had given similar results in non - hemoglobin contaminated samples (table 3 and 4). The density 
of cytochrome P450 enzymes were in the range of 0.28 - 0.99 nmole/mg of protein. The density 
of cytochrome P450 enzymes was allometrically related with the body weight (p<0.05) (figure 
9).  
Substrate depletion approach: The incubation conditions for substrate depletion approach were 
optimized, such as optimal microsomal concentration for incubation (0.5 mg/mL); time of pre-
incubation (3 min); temperature of incubation (37 
0
C); the range of vinblastine concentrations to 
be used (0.025 – 61.65 μM), time points to stop; and stop solution to use. The concentrations of 
vinblastine in the incubate samples were quantified by a RP-HPLC. The intraday and interday 
accuracy and precision were within the acceptable limits. A typical substrate depletion profile of 
vinblastine in microsomal incubations was shown in figure 11. 1/x
2
 weighting scheme was used 
for the quantification. The limit of quantitation of the assay was 10 ng/mL. No metabolite was 
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seen either with fluorescence or ultra violet (UV) detection (figure 10). The best model for fitting 
of substrate depletion data to determine the values of Vmax and Km was chosen based on 
coefficient of variation (CV) %, residual plots, and inspection of the fitted plots. 1/y weighting 
scheme was used for model fitting of the substrate depletion data. A representative model fitting 
of substrate depletion data was presented in figure 12 similar to a Michaelis-Menten enzyme 
kinetic profile. The range of values of Vmax, Km, and intrinsic clearance (CLint) of vinblastine were 
22 – 265 pmoles/min/mg of protein, 2.5 – 40 μM, and 5.25 – 70.12 mL/min/kg, respectively. The 
in vivo CLint and hepatic clearance of vinblastine determined in vitro were allometrically related 
to body weight (p<0.05) (figures 13 and 14). 
In vivo vinblastine pharmacokinetic studies: Pharmacokinetics of vinblastine in dogs was best 
described by three – compartmental model with 1/y weighting scheme, and Gauss-Newton 
(Levenberg and Hartley) integration method. Appropriate model was chosen based on low CV%, 
AIC values, and inspection of residual plots and plasma concentration versus time plots. Plasma 
concentrations of vinblastine declined sharply following the bolus administration of vinblastine 
sulfate (figure 15). The concentrations of vinblastine were above the limit of quantitation in both 
plasma and urine samples in all dogs. The pharmacokinetic parameters of vinblastine were 
presented in table 5. The excretion profile of vinblastine in urine was presented in figure 16. The 
percent recovery of vinblastine in urine out of total dose administered was 11.6 ± 2.1 (mean ± 
SD). Although desacetylvinblastine (DVLB) was noticed in plasma and urine samples, the 
appearance of DVLB did not give any information in terms of rate of metabolism. Hepatic 
clearance of vinblastine was determined by subtracting the renal clearance of vinblastine from the 
total clearance of vinblastine and was plotted against the body weight to establish the allometric 
relationship (figure 17).  
In vitro / in vivo correlations:  
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In vitro / in vivo correlations were established for hepatic clearance of vinblastine. In table 6, the 
percent accuracy of prediction of hepatic clearance of vinblastine with different predictive models 
was presented. Parallel tube model predicted hepatic clearance of vinblastine with better accuracy 
compared to the other two models. Different statistical tests, such as afe, mse, and rmse were 
performed and presented in table 7. In corroboration with percent accuracy of predictive models 
in table 6, the statistical methods also gave similar results. The co-efficient of determination 
between predicted hepatic clearance and observed hepatic clearance of vinblastine was 1 (figure 
18).    
Discussion 
Organ scaling: No difference was noted between the slopes and y-intercepts of adults and 
juveniles. Therefore, the data was combined and analyzed as a single data with the inclusion of 
significant factor ontogeny term in the final regression equation. In conformation with previous 
studies, gender was not a significant predictor of liver weight (p>0.05) (Prothero, 1982). The 
canine intraspecies allometric exponent of liver was 0.9, whereas the previously reported 
interspecies allometric exponent of liver was 0.886. The newly developed allometric equation 
was validated using both training data set per se and validation data set. For the data in validation 
data set, detailed histopathology and post-mortem reports were available. The residual plots of 
both training and validation data set showed that the residuals of liver weights determined from 
allometric equation were randomly distributed. In contrast, residuals of liver weights determined 
as a function of fixed proportion of body weight had diagonal and skewed distribution (figures 2 
and 3).  Further, the sums of absolute residuals have shown the better predictive ability of the 
newly developed equation compared to the 3.5 % fixed proportion of body weight in both training 
and validation data sets. The average % relative weights of liver (that is, liver weight (g)*10
-3
 ÷ 
body weight (kg)) in training and validation data sets were 4.47 and 3.93, respectively. As 
demonstrated in the residual and scatter plots (figures 2, 3, and 4), and the values of % relative 
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liver weights in this studies, 3.5% of fixed proportion of body weights is under estimating the 
weights of liver.  The percent fixed proportion of body weights for liver reported in the previous 
studies based on few number of subjects were 2.36 ± 0.38 (mean ± SD) (Steward et al., 1975), 
3.04 (Jackson and Cappiello, 1964), and 3.29 (Reber et al., 1961). Fixed proportions of body 
weight approach considers only body weight as significant determinant of liver weight whereas 
allometric equation developed in this study considers both body weight and ontogeny which were 
significant determinants of liver weights. The newly developed allometric equation is more robust 
compared to previous similar studies in terms of number, pool of different breeds, and range of 
body weights considered. The newly developed equations could be used in predictive software 




Microsomal purification: Purification of microsomes was done successfully. The values of 
microsomal protein concentrations and density of cytochrome P450 enzymes were within the 
reported literature values (Smith et al., 2008). In order to achieve good quality of microsomes, 
exposure to air should be minimized as exposure might reduce the potency of enzymes through 
oxidation.  
Cytochrome P450 density: Hemoglobin contamination was noticed in microsomal samples 
which were purified from frozen liver samples. Hemoglobin contamination was evidenced by the 
appearance of a peak at 420 nm, altered peak shape at 450 nm with classical carbon monoxide 
difference spectra (Omura and Sato, 1964b; Omura and Sato, 1964a). Also, the microsomal 
samples processed from fresh liver samples were light straw colored while microsomes purified 
from frozen liver samples were dark red in color.  The density of cytochrome P450 enzymes 
allometrically related to body weight (p<0.05). With the increase in body weight, the density of 
cytochrome P450 enzymes had decreased. This phenomenon is in conformation with the earlier 
findings that cellular metabolism is allometrically related to body size (Porter, 2001). Also, this 
120 
 
allometric dependence of cytochrome P450 enzymes answers why larger individuals receive 
lesser dose per unit body weight compared to smaller individuals within the same species.  
Intrinsic clearance: Ideally, the kinetic behavior of an enzyme is assessed by monitoring rates of 
product or metabolite formation at various substrate concentrations. However, standards for 
metabolites may not be available or metabolites may not be identified. In such cases, alternative 
approaches, such as substrate depletion approach and in vitro half - life methods are used. In the 
preliminary studies, no metabolite was recognized which could be used to perform classical 
Michaelis-Menten kinetics based on the rate of product or metabolite formation. Therefore, 
substrate depletion approach which is emerging as a potential in vitro method to characterize 
kinetic behavior of an enzyme was used (Obach and Reed-Hagen, 2002; Komura et al., 2005; 
Nath and Atkins, 2006). As kinetic characterization of metabolite or product is not required, this 
method is well suited for the new chemical entities (NCEs) and drugs for which standards of 
metabolites are not available. There are some studies which have shown similar results with 
substrate depletion approach and classical Michaelis-Menten kinetics (Stringer et al., 2009). To 
the best of authors’ knowledge, studies on in vitro metabolism of vinblastine in dogs were not 
published elsewhere.  As there was no published literature on microsomal incubations in dogs, the 
microsomal incubation conditions were optimized and incubations were conducted successfully. 
Optimization of initial conditions is important as Michaelis - Menten parameters are determined 
in vitro under linear conditions with respect to time of incubation and microsomal protein 
concentration. In microsomal substrate depletion studies, an initial apparent rise in the 
concentrations of substrate was observed which might be due to slow solubilization of drug into 
microsomes. Similar observations were found elsewhere also (Obach, 2011). To avoid errors, 
substrate depletion up to 20% of initial concentration was considered for the calculation of rate of 
reaction (Nath and Atkins, 2006). This study is the first of its kind to consider different body 
weights in in vitro drug metabolism studies. The study had produced robust estimates of Vmax, Km, 
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and intrinsic clearance of vinblastine in 23 dogs weighing from 2.3 – 54 kg. It is noteworthy to 
recognize that both density of cytochrome P450 enzymes and intrinsic clearance of vinblastine 
were allometrically related to body weight. These findings explain allometric dependence of 
hepatic enzymes which explains why larger individuals receive lesser dose per unit body weight. 
Hepatic clearance: The intrinsic clearance of vinblastine was integrated with other physiological 
parameters which influence clearance, such as hepatic blood flow and fraction of free drug in 
plasma to determine hepatic clearance. Considering the simple forms of hepatic predictive 
models, the fraction of unbound drug in microsomes was assumed as 1. Three different predictive 
models were used. There are underlying assumptions for each predictive model but all of them 
share some common assumptions, such as perfusion rate limited distribution of drug, rapid 
diffusion of drug into hepatocytes, and homogenous distribution of enzymes in the liver (Houston 
and Carlile, 1997; Ito and Houston, 2004). Well-stirred model (equation 1) which is the simplest 
of three models assumes that the liver is a single well-stirred compartment and drug is mixed 
infinitely well inside the liver. Parallel tube model (equation 2) assumes that the liver is 
composed of a number of identical and parallel tubes with enzymes distributed evenly in each 
cross-section, and blood flows in one direction. The drugs are mixed along a flow path from input 
to output of the liver only in the infinitely small section. Dispersion model (equation 3) is 
described based on the analysis on the distribution of the hepatic residence time of drugs after the 
bolus injection into the liver. Dispersion model is considered to be described based on the flow 
dynamics in the liver more relevant than the other two models.   Dispersion number (DN) 
indicates the extent of dispersion of drugs in the liver. The dispersion model becomes well stirred 
model when the dispersion is infinite and parallel tube model when no dispersion is noticed (Pang 
and Rowland, 1977; Chiba et al., 2009). As expected, based on the results of allometry of 
cytochrome P450 density and intrinsic clearance with body weight, hepatic clearance of 
vinblastine allometrically related with body weight (p<0.05).  
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In vivo studies: A highly sensitive and specific analytical method - liquid 
chromatography/atmospheric pressure chemical ionization-tandem mass spectrometry, was 
developed with the limit of quantitation of 0.125 ng/mL for both VLB and DVLB and in both 
urine and plasma matrices. To the best of authors’ knowledge, this was the first analytical method 
developed to quantify the concentrations of VLB and DVLB simultaneously in plasma and urine 
samples of dogs. As described previously in humans, the disposition of vinblastine following IV 
administration was best described by a three-compartmental model (Owellen et al., 1977). 
However, two compartmental modeling of disposition was also reported in dogs (Creasey et al., 
1975). With the increase in body weight, the total clearance of vinblastine per unit body weight 
had decreased while AUC, a dose dependent parameter had increased with the increase in body 
weight. Unlike other drugs, AUC correlates with the therapeutic efficacy and toxicity of cancer 
chemotherapic drugs (Moore and Erlichman, 1987; Calvert et al., 1989; Warmerdam, 1997; 
Hempel and Boos, 2007). The percent recovery of vinblastine in urine samples was 11.6 ± 2.1 
(mean ± SD). These values indicate that approximately 12% of the total dose administered is 
excreted in the urine. Similar percent recoveries were reported in humans (Owellen et al., 1977). 
The mechanism of renal excretion of vinblastine was established as renal secretion (de Lannoy et 
al., 1994). Also, these results support that hepatic metabolism is the major route of metabolism 
for vinca alkaloids. The in vivo vinblastine pharmacokinetic study would have been strengthened 
by more number of animals with different body weights for a robust allometric equation. 
However, these studies are proof-of-concept studies to lay foundation for a definitive research in 
large number of dogs.   
In vitro/in vivo correlations: Correlations between in vitro studies and in vivo studies in limited 
sample size are gaining more importance because of their wide applicability. Such correlations 
would decrease number of live animal studies and increase the speed of pre-clinical drug 
development process. The percent of accuracy and statistical tests performed to test the predictive 
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ability of in vitro metabolism studies also had given satisfactory results for all three predictive 
models. In fact, all these predictive models are derived from mass balance relationships. If the 
predicted value is equal to actual value, then the average fold error would be equal to one. The afe 
would be equal to 2 if the predicted value is within 100% above or 50% below the observed value 
(Sheiner and Beal, 1981). Similar statistical analysis to evaluate in vitro methods were done and 
an afe value ≤ 2 was considered successful (Obach et al., 1997). Correlation coefficient values 
were similar for all three predictive models. Based on afe, and rmse values, the predictive ability 
of the models is in the order of parallel tube > dispersion model > well-stirred model. Previous 
work also reported similar results (Ito and Houston, 2004). These studies have clearly shown the 
applicability of in vitro studies in predicting in vivo pharmacokinetic parameters successfully.  
Clinical applicability 
Using the standard equation, Dose = AUC ∙CLtotal and by substituting the clearance term with the 
allometric equation developed in this study as a function of body weight, the dose of vinblastine for 
a desired therapeutically relevant drug exposure can be accurately calculated: Dose = AUC ∙ (21.6 ∙ 
BW
0.78
). In silico calculations were performed to demonstrate the utility of this novel approach to 
determine the doses of vinblastine to treat mast cell tumors in dogs. Based on the current dose rate 
of vinblastine, 2 mg/m
2
 to treat mast cell tumors in dogs (Rassnick et al. 2008) and clearance 
predicted from the novel allometric equations, the drug exposure (AUC) was calculated in a 20 kg 
body weight dog.  
Approximate body surface area in m
2
 = (10.1 x (weight in grams)
2/3
 )/10000  
       = (10.1 x (20000)
 2/3
)/10000 = 0.74417 m
2
  
AUC (drug exposure) = Dose / Clearance = (0.744 x 2) / (21.6 x (20
0.78
)) = 0.00666 mg∙min/mL 
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Using this value of drug exposure as target value, doses of vinblastine were calculated using both 
BSA dosing methodology and new dosing equation. The percent difference between the drug 
exposure calculated by the current BSA dosing methodology and target drug exposure calculated by 
the newly developed allometric equation were presented in table 8. As expected, the percent 
difference of AUC calculated with BSA approach from the target drug exposure was more at the 
extremes of body weights of dogs. From these values, it could be concluded that smaller dogs are 
over dosed and larger dogs are under dosed. Therefore, dog breeds, such as boxers, Labrador 
retrievers, golden retrievers, Schnauzers, and Shar peis which have higher predilection for mast cell 
tumors are receiving subtherapeutic doses. The newly developed allometric equation for the 
accurate calculation of doses of vinblastine in dogs to treat mast cell tumors and other responsive 
modalities is expected to normalize the drug exposure between disparate canine patients. Clinical 
studies are suggested to test the newly developed dosing equations. 
Conclusions  
In summary, a robust allometric equation was developed to predict the weight of liver in 
dogs. For the first time, allometric dependence of density of cytochrome P450 enzymes on body 
weight was shown in dogs; intrinsic clearance of vinblastine was determined in dogs using 
substrate depletion approach. Hepatic clearance of vinblastine was predicted using well-stirred 
model, parallel tube model, and dispersion model with acceptable predictive ability. An 
allometric equation was developed to determine the value of hepatic clearance of vinblastine in 
dogs for a given body weight. In vivo vinblastine pharmacokinetic studies were conducted to 
compare the results of in vitro studies.  In vitro/in vivo correlations were established for the 
hepatic clearance of vinblastine in dogs. A new dosing equation was developed to accurately 
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  Allometric 3.5% of body weight 
Liver Juvenile 3.8 11.4 
 Adult 8.1 8.5 
 Total 11.9 19.9 
 
Table 1. Sum of absolute residual errors from predictions of liver weights using newly developed 
allometric equation and 3.5% fixed proportion of body weight in the training data set per se. 
 
 
  Allometric 3.5% of body weight 
Liver Juvenile 1.7 2.7 
 Adult 7.1 6.6 
 Total 8.8 9.2 
 
Table 2. Sum of absolute residual errors from predictions of liver weights using the newly 





















Ascorbate and PES 
reduced dithionate 
difference spectra 
B3040 20.5 ± 1.2 17.7 ± 0.8 19.1 ± 0.8 17.3 ± 0.4 
7950 17.7 ± 0.4 16.2 ± 0.6 17.3 ± 0.2 16.1 ± 0.2 
55-82-91 21.2 ± 0.6 20.7 ± 0.6 19.6 ± 0.8 19.3 ± 0.4 
 
Table 3. The cytochrome P450 density determined in duplicate in non-hemoglobin contaminated 
microsomal samples by four methods  revealed that the carbon monoxide difference spectra and 















Ascorbate and PES 
reduced dithionate 
difference spectra 
08OKC51 16.7  ± 1.5 21.3 ± 0.2 20.1 ± 1.4 18.3 ± 0.7 
08OK52 10.5 ± 0.3 15.8 ± 0.4 15.8 ± 1.2 14.3 ± 0.1 
08OKC84 10.3 ± 0.4 11.3 ± 0.1 10.4 ± 0.8 10.0 ± 0.1 
 
Table 4. The cytochrome P450 density in microsomal samples contaminated with hemoglobin 
was also compared by all four methods. Dithionate difference spectra and dithionate difference 
spectra reduced with ascorbic acid had similar values to one another without interference from the 




Body weight (kg) 10.6 11.3 43 54 
K10 (1/hr) 1.0 0.9 0.52 0.51 
alpha_HL (hr) 0.02 0.02 0.04 0.01 
beta_HL (hr) 0.45 0.37 0.4 0.81 
gamma_HL(hr) 19 16 20 29 
Cmax (ng/mL) 106 75 76.75 64.45 
Vss (mL/kg) 18039 18817 13234 23719 
CL (mL/hr/kg) 703 858 508 598 
AUC (ng.hr/mL) 107 87 148 125 
AUMC (ng.hr.hr/mL) 2735.9 1918.2 3842 4980 
MRT (hr) 25.65 21.94 26 40 
 
Observed maximum plasma concentration (Cmax), Elimination rate constant (K10), half - life of 
rapid distribution phase (Alpha_HL), half – life of  slow distribution phase (Beta_HL), half-life of 
elimination phase (Gamma_HL), Volume of distribution at steady state (Vss), Plasma clearance 
(CL), Area under the curve from administration to infinity (AUC), Area under moment curve 
(AUMC), Mean residence time (MRT) 
Table 5. Important pharmacokinetic parameters (mean ± SD) of vinblastine estimated by 
compartmental analysis in four adult male dogs (10 -54 kg) after an intravenous bolus 


















11.3 148.47 111 (-25%) 131 (-12%) 124 (-17%) 
10.6 110.47 106 (-3.9%) 125 (13%) 118 (7%) 
43 324.41 291 (-10%) 325 (0.2%) 311 (-4%) 
53.64 447.67 341 (-24%) 378 (-16%) 363 (-19%) 
 
Table 6. Table showing the actual hepatic clearance of vinblastine measured in four adult male 
dogs (10 - 54) and predictive ability of three predictive models. Out of three predictive models, 
parallel tube model had predicted hepatic clearance with less % difference from the observed 
values.   
 
 Well-stirred model Parallel tube model Dispersion model 
afe 1.19 1.03 1.08 
rmse 1.96 1.20 1.35 
r
2 0.85 0.85 0.85 
 
Table 7. Statistical data comparing the accuracy of predictions with the three predictive models.  
All three models have predicted hepatic clearance with acceptable statistics. However, parallel 



























0.9 22.1 0.1 0.15 0.09 0.19 0.21 0.0095 42.1 
5 15.2 0.5 0.10 0.30 0.59 0.12 0.0078 17.0 
10.6 12.8 0.9 0.09 0.49 0.97 0.09 0.0072 7.5 
11.3 12.7 1.0 0.08 0.51 1.02 0.09 0.0071 6.7 
20 11.2 1.5 0.07 0.74 1.49 0.07 0.0067 0.0 
43 9.4 2.7 0.06 1.24 2.48 0.06 0.0061 -8.3 
53.6 9.0 3.2 0.06 1.44 2.87 0.05 0.0060 -10.6 
60 8.8 3.5 0.06 1.55 3.10 0.05 0.0059 -11.7 
90 8.0 4.8 0.05 2.03 4.06 0.05 0.0056 -15.7 
 
Table 8. Comparison of current BSA dosing methodology and newly developed allometric 
equation. Drug exposure calculated using BSA dosing approach was compared with the target 
drug exposure (0.00667 mg.min/mL) calculated in a 20 kg body weight dog. The percent 
difference of AUC calculated with BSA dosing approach was more pronounced at the extremes 












Figure 1. Intraspecific allometry of liver weights in dogs. The data was collected from a total of 
160 dogs (58 juveniles and 102 adults). Log10 transformed liver weights were regressed against 
log10 transformed body weights. The liver weight allometrically related to body weight and 






=0.93, Sy.x = 0.094, Where, for 
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= 0.93, Sy.x = 0.094 







Figure 2. The residuals of log10 transformed liver weights predicted with newly developed 
allometric equation and 3.5% fixed proportion of body weights were plotted against body weights 
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Figure 3. The residuals of log10 transformed liver weights predicted with newly developed 
allometric equation and 3.5% fixed proportion of body weights were plotted against body weights 
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Figure 4. Scatter plots of measured liver weight (g) against body weight (kg) of validation data 
set. The solid line indicates the regression line of predicted liver weight using the newly 
developed allometric equation. The dashed line indicates predicted liver weights as 3.5% fixed 














Body weight (kg) 
Measured Juvenile Liver Weight
Power (Allometric)














Body weight (kg) 
Measured Adult Liver Weight
Power (Allometric)




Figure 5.  A representative spectrophotograph showing the peak at 450 nm with carbon 
monoxide difference spectrum.  
 
Figure 6. A representative spectrophotograph showing the obscured peak at 450 nm and a more 
pronounced peak at 419 nm in hemoglobin contaminated microsomal sample using carbon 




Figure 7. A representative spectrophotograph showing the reduced peak at 425 nm without 
affecting peak at 450 nm in hemoglobin contaminated microsomal sample using dithionate 
difference spectra. 
 
Figure 8. A representative spectrophotograph showing the reduced peak at 425 nm without 
affecting peak at 450 nm in hemoglobin contaminated microsomal sample using ascorbate 





Figure 9. Scatter plot showing the allometric relationship between cytochrome P450 density 
(nmole/mg of protein) and body weight (kg). With the increase in body weight, the density of 
cytochrome P450 enzymes had decreased (p<0.05). 
 
 
y = 1.23x-0.23 










































































Figure 12.  A representative model fitting of substrate depletion approach data of vinblastine 
microsomal incubations similar to Michaelis-Menten enzyme kinetics. The rate of reaction had 
increased with the increase in the substrate concentration reaching the theoretical maximum rate 
of reaction (Vmax).  
Substrate concentration Vs. Rate of reaction
Substrate concentration (µM)







































Figure 13.  Scatter plot showing the allometric relationship between body weight (kg) and 
predicted in vivo intrinsic clearance of vinblastine (mL/min/kg) on logarithmic coordinates. With 
the increase in body weight, the in vivo CLint had decreased (p<0.05). 
CLint (in vivo)= 47.8 BW
0.55 
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Figure 14.  Scatter plots showing the allometric relationship between hepatic clearances of 
vinblastine (mL/min) predicted in vitro using well-stirred model (equation 1), parallel tube model 
(equation 2), and dispersion model (equation 3) and body weight (kg) on logarithmic coordinates. 
With the increase in body weight, the hepatic clearance of vinblastine per unit body weight 
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0.69 






















Figure 15: A representative 3-compartmental model fitting of vinblastine in a 54 kg body weight 
adult and 5 kg body weight juvenile dog following intravenous bolus administration of 
vinblastine at the rate of 0.075 mg/kg. Circles represent observed concentrations and dots indicate 
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Figure 16. Excretion of vinblastine in urine following an intravenous dose of 0.075 mg/kg 
vinblastine. The percent recovery of vinblastine in urine was 11.6 ± 2.1 (mean ± SD) out of total 



























Figure 17. Scatter plot showing the allometric relationship between hepatic clearance of 
vinblastine determined in four adult male dogs (10 - 54 kg) and body weight (kg). With the 
increase in body weight, the hepatic clearance of vinblastine per unit body weight had decreased.  
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Figure 18. Correlation between hepatic clearances of vinblastine determined in vivo in four adult 
male intact dogs (10 – 54 kg) and in vitro hepatic clearance of vinblastine determined by the 
allometric equation of parallel tube model (figure 14). An R
2 
value of 0.97 indicates good 
predictive ability of the in vitro method to predict the hepatic clearance of vinblastine in dogs. 
 




























SIMULTANEOUS QUANTIFICATION OF VINBLASTINE AND 
DESACETYLVINBLASTINE CONCENTRATIONS IN CANINE PLASMA AND 





A highly sensitive and specific liquid chromatography-atmospheric pressure chemical ionization-
mass spectrometry (LC/APCI-MS/MS) method has been developed and validated for 
simultaneous quantification of vinblastine and its metabolite, desacetylvinblastine, in canine 
plasma and urine samples. Plasma and urine samples were processed by a solid phase extraction 
procedure. The optimal chromatographic behavior of these analytes was achieved on 
pentafluorophenyl (PFP) propyl analytical column (5 μm, 50 x 2.1 mm) under isocratic elution of 
0.75 mL/min with a mobile phase of 5 mM ammonium acetate and methanol. The samples were 
analyzed in positive ion, multiple reaction monitoring mode. The calibration curves were linear 
over 0.125 - 2 ng/mL (lower calibration curve); 2 - 100 ng/mL (higher calibration curve) and 
0.125 - 5 ng/mL for vinblastine and desacetylvinblastine in plasma, and over 1 - 2000 ng/mL and 
0.5 - 100 ng/mL for vinblastine and desacetylvinblastine in urine samples, respectively. The 
limits of quantitation of vinblastine and desacetylvinblastine were 0.125 ng/mL in both matrices. 
The intra- and inter-day accuracy was above 89% and precision below 8.6% for both analytes in 
both matrices. The developed method was successfully applied to ongoing in vivo vinblastine 
pharmacokinetic studies in dogs. 
Keywords: vinblastine, desacetylvinblastine, vinorelbine, dog, LC/MS/MS, analysis 
Introduction 
 
Vinblastine (vincaleucobastine; VLB) is a vinca alkaloid isolated from dicotyledonous 
Madagascar periwinkle plant, Catharanthus roseus (family: Apocyanaceae). Vinblastine was the 
first vinca alkaloid isolated and has been used for the treatment of soft tissue tumors both in 
human and veterinary medicine as a single agent or in combination with other anticancer drugs. 
4-O-desacetylvinblastine (DVLB) is a human metabolite of vinblastine that is itself considered to 
be a potent and active anticancer xenobiotic (Owellen et al., 1977) . Vinca alkaloids work by 
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binding to beta-tubulin and preventing the formation of microtubules during mitosis, thereby 
arresting cell division (Gan and Kavallaris, 2008; Kavallaris et al., 2008; Cheng et al., 2009). 
Vinca alkaloids were also shown to inhibit angiogenesis (Pasquier and Kavallaris, 2008). In order 
to increase the therapeutic utility or decrease the potential for toxic side effects, semi-synthetic 
vinca alkaloids, such as vinflunine, vindesine sulfate and vinorelbine (VRB) were developed. 
Although all of these vinca alkaloids share common features in structure and affinity to 
microtubules, there is variability in their therapeutic efficiency, therapeutic indications, and 
toxicities (Damen et al., 2009). Currently, toxicity adjusted dosing is the most accepted method of 
dose adjustment for vinblastine administration in dogs (Rassnick et al., 2008; Welle et al., 2008). 
A variety of methods, including radioimmunoassay and high performance liquid chromatography 
(HPLC) coupled with ultraviolet (UV), fluorescence, or electrochemical detection have been used 
to quantify vinblastine concentrations in biological matrices (van Tellingen et al., 1991; van 
Tellingen et al., 1993; Gupta et al., 2005; Puozzo et al., 2007). A reversed phase - 
HPLC/fluorescence method was successfully developed in this laboratory for the analysis of 
vinca alkaloids with a maximal sensitivity of 1 ng/mL. Incurred sample analysis indicated the 
need of even higher sensitive method below 1 ng/mL. To the best of authors’ knowledge, there 
are no published reports on highly sensitive and specific analytical methods to quantify the 
concentrations of vinblastine and desacetylvinblastine in the biological matrices of dog. The 
literature indicated successful liquid chromatography tandem mass spectrometry (LC/MS/MS) 
methods below this level (Ramirez et al., 1997), so this laboratory began pursuing an LC/MS/MS 
method based on a previously published method to measure vinorelbine (Niwa and Kawashiro).  
In LC/MS/MS, monitoring precursor drug mass and product ion fragment mass gives high 
specificity in the quantitation of a drug. Sensitivity of the LC/MS/MS is also higher than other 
analytical methods. The use of LC/MS/MS is becoming more prevalent in drug metabolism and 
in vitro screening of new chemical entities (NCEs) in drug development process because of its 
high sensitivity and specificity (Hsieh, 2008).   
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In this paper, a highly sensitive and specific liquid chromatography / atmospheric pressure 
chemical ionization – tandem mass spectrometry (LC-APCI-MS) analytical method was 
developed to simultaneously quantify vinblastine and desacetylvinblastine concentrations in 
canine plasma and urine samples. The developed method was successfully applied to the in vivo 
pharmacokinetic study of vinblastine in dogs. 
Materials and methods 
 
Chemicals and materials:  
Vinblastine sulfate (C46H58N4O9·H2SO4) solution (1 mg/mL) was purchased from APP 
Pharmaceuticals LLC, Schaumburg, IL, USA. Vinorelbine tartrate (C45H54N4O8 ∙2C4H6O6) 10 
mg/mL was purchased from Teva, North Wales, PA, USA. 4-O-desacetylvinblastine 
(C44H56N4O8) was purchased from Council of Europe, European Pharmacopeia, Strasbourg, 
Cedex, France.  HPLC – grade ammonium acetate, methanol, and acetonitrile and silanized 
glassware were purchased from Fisher Scientific Company, New Jersey, NJ, USA. Oasis
®
 HLB 1 
mL solid phase extraction cartridges were purchased from Waters
®
 Corporation, Milford, MA, 
USA.  
Liquid chromatography/Mass spectrometry 
A Schimadzu HPLC system (Shimadzu corporation, Kyoto, Japan) consisted of a system 
controller (CBM-20A), binary solvent delivery unit (LC-20AD), in-line degasser (DGU-20A5), 
an auto-sampler (SIL-20AC) with thermostatic injector set at 4 0C and a column oven set at 40 
0C (CTO-20AC) with a Restek Allure Pentafluorophenyl (PFP) Propyl 5 μm 50 x 2.1 mm 
column (Restek, Bellefonte, PA), and guard cartridge (Restek 5 μm, Ultra Biphenyl, 10 x 2.1 
mm) were used. An Applied Biosystems 4000 Q-Trap MS/MS system (Applied Biosystems, 
Foster City, CA) equipped with an atmospheric pressure chemical ionization source and a 
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NitroGen N300DR nitrogen generator was used (Peak Scientific Instruments Ltd, Paisley, United 
Kingdom). Analyst
®
 1.5 software for Windows
®
 was used to acquire and analyze the data.   
Mobile phase 
The mobile phase consisted of 10% 5 mM ammonium acetate buffer, adjusted to a pH of 3.5 with 
glacial acetic acid, and 90% HPLC grade methanol. Separation was achieved by isocratic elution 
at a flow rate of 0.75 mL/min.  
Preparation of stock solutions 
All stock and working solutions of analytes were prepared under an externally vented fume hood 
per chemotherapy safe handling and administration standards (Hayes, 2005; Connor and 
McDiarmid, 2006; Eisenberg, 2009). Stock solutions and working solutions for all three analytes 
were prepared in methanol using silanized glassware as vinca alkaloids are known to adsorb onto 
glassware (Puozzo et al., 2007; Zorza et al., 2007). All stock solutions were stable at - 20 
0
C for 
up to 9 months. Depending on the necessity of sensitivity in each matrix, different ranges of 
calibrating concentrations for vinblastine and desacetylvinblastine were used. For vinblastine , a 
range of calibrators (6.25 to 5,000 ng/mL for plasma samples; 500 to 100,000 ng /mL for urine 
samples) were prepared. For desacetylvinblastine, 6.25 to 250 ng/mL for plasma samples and 25 
to 5,000 ng/mL for urine samples were prepared. Vinorelbine was used as the internal standard; 
stock solution was prepared at the concentration of 100,000 ng/mL and working internal standard 
solution was prepared at the concentration of 500 ng/mL. All calibrators were stable for at least 3 
months at 4 
0
C. 
Sample preparation for plasma and urine 
For calibrants and quality controls, 480 μL of blank plasma or urine were added to micro-
centrifuge tubes. Ten micro liters of vinblastine and 10 μL of desacetylvinblastine calibrator 
solutions in methanol were added to achieve final concentrations of 0.125 - 100 ng/mL and 0.125 
- 5 ng/mL for plasma samples; 1 – 2,000 ng/mL and 0.5 - 100 ng/mL for urine samples, 
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respectively. Incurred samples from dogs were thawed at room temperature and 500 μL of sample 
matrix were added to labeled micro centrifuge tubes. All samples were diluted with 500 μL water 
containing 10 μL of 500 ng/mL vinorelbine and vortex mixed. Oasis
®
 HLB cartridges were 
preconditioned with 1 mL of methanol and 1 mL of water. Samples were loaded onto the column 
slowly, at a rate of approximately 1 – 2 drops per second. Cartridges were washed with 2 mL of 
water, and then dried at maximum airflow for 30 minutes. Samples were slowly eluted with 2 mL 
of methanol into labeled silanized glass tubes. The eluted samples were dried under nitrogen at 30 
0C and were resuspended in 150 μL of buffer, containing 50% 5 mM ammonium acetate, 25% 
acetonitrile, and 25% methanol. For plasma samples, 100 μL of the redissolved sample was 
injected onto the system, whereas 20 μL were injected for urine samples. Silanized glassware was 
used wherever possible during sample preparation to avoid systemic under-estimation of analyte 
concentration and to increase sensitivity (Trim et al., 2008; Damen et al., 2009; Damen et al., 
2010) .  
Calibration curve 
For the quantification of vinblastine and desacetylvinblastine concentrations in experimental 
samples, the ratio of peak area of vinblastine or desacetylvinblastine to the peak area of the 
internal standard, vinorelbine, was used. For vinblastine, two calibration curves were prepared in 
plasma samples to obtain acceptable linearity of calibration curves, whereas only one calibration 
curve was used for urine samples. For desacetylvinblastine, only one calibration curve was used 
in both matrices. At least 6 calibrators were included for each calibration curve. Different 
weighting schemes were used for each analyte; 1/x weighting was used for high and low 
vinblastine calibration curves. For desacetylvinblastine, no weighting was used for plasma curves, 
whereas 1/x
2
 weighting was used for urine calibration curves. The best weighting model was 
chosen based on the accuracy of calculated concentrations and coefficient of determination (R
2
) 
value. The limit of quantitation was defined as accuracy and coefficient of variation within 20% 
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of nominal concentrations. Acceptability criteria for all runs included accuracy within 15% in at 
least four concentrations in the calibration curve above the LOQ and an R
2
 of 0.99 or above. 
Method validation 
Matrix effects, recovery efficiency, and process efficiency were determined for validation of 
vinblastine and desacetylvinblastine in plasma and urine. Samples were prepared in triplicate at 5 
ng/mL concentration for each analyte. Matrix effect (ME) was determined as the percentage of 
the ratio of  peak areas of analytes fortified after extraction (B) to peak areas of analytes in 
resuspending buffer (no extraction) (A) (Matuszewski et al., 2003). Recovery efficiency (RE) was 
calculated as the percentage of peak areas of analytes fortified before extraction (C) to peak areas 
of analytes fortified after extraction (B). Process efficiency (PE) was determined as the 
percentage of peak areas of analytes fortified before extraction (C) to peak areas of analytes in 
resuspending buffer (no extraction) (A).  
ME (%) = B/A x 100 
RE (%) = C/B x 100 
PE (%) = C/A x 100 
In addition to the assessment of calibration curve performance, intraday and interday accuracy 
and precision values were calculated in five replicate samples for each analyte in plasma and 
urine. The precision was calculated as the relative standard deviation (RSD), or standard 
deviation divided by the mean concentration, and expressed as a percentage. Accuracy within 
20% of the nominal concentration at the lower limit of quantitation (LLOQ) and 15% of the 
nominal concentration at all higher concentrations were set as the acceptable limits. Similarly, an 





To assess the assay’s ability to measure the concentrations of each analyte distinctly in the 
presence of other analytes, peak areas of each analyte were compared by injecting each analyte 
alone and in the presence of other analytes in resuspending buffer and after extraction in sample 
matrices. The selected reaction monitoring (SRM) traces of each ion for each analyte and blank 
plasma were compared. 
Sensitivity 
In addition to evaluation of the lowest concentration that met accuracy and precision criteria of 
20% at the LLOQ, a multiple calibration curve method, deemed the statistical method, was used 
to estimate the limit of detection (LOD) and LLOQ using triplicate calibrants in the range of 0.1 
to 10 ng/mL in plasma. After linear regression of the resulting concentration versus response 
curves, the y-intercept and slope of each best fit line were used to calculate the standard deviation 
(SD) of the y-intercepts and the mean of the slopes of calibration curves.  The LOD was 
calculated as (3.3 * SD of the y-intercepts) / (mean of the slopes of calibration curves).  The LOQ 
was calculated as (10 * SD of the y-intercepts) / mean of the slopes of calibration curves 
(Armbruster et al., 1994). 
Freeze-thaw stability 
Freeze-thaw stability of plasma samples stored at – 80 
0
C was evaluated by fortifying blank 
samples with vinblastine at 10 ng/mL and 50 ng/mL and desacetylvinblastine at 0.5 and 2 ng/mL, 
in triplicate. One batch of fortified plasma samples were frozen and thawed twice while the other 
batch of fortified plasma samples were thawed only once before sample processing.  
Application to in vivo vinblastine pharmacokinetic study in dogs 
The novel highly sensitive analytical method was successfully applied to quantify the 
concentrations of vinblastine and desacetylvinblastine in plasma and urine samples of four adult 
and two juvenile dogs (4 – 54 kg) that received an intravenous bolus dose of 0.075 mg/kg 
vinblastine sulfate. Plasma and urine samples were collected at pre, 2 min, 5, 10, 15, 20, 30, 45 
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min, 1 hr, 2, 3, 4, 5, 6, 9, 12, and 24 hrs post drug administration; pre sample, 1 hr, 3, 7, 12, 24, 
32, 48, 56, and 72 hr, respectively following vinblastine sulfate administration, respectively. The 
data was analyzed on WinNonlin® 5.2 pharmacokinetic software (Pharsight Corp., Mountain 
View, CA) to analyze the pharmacokinetic parameters.  
Results and discussion 
Sample pretreatment optimization 
Different sample pretreatment procedures were investigated to optimize sample recovery and 
chromatography. Published liquid -liquid extraction procedures were investigated using different 
solvents such as: a mixture of hexane and ethyl acetate, chloroform and isopropanol, and ether 
(Ramirez et al., 1997). Liquid-liquid extraction was unsuccessful due to poor recovery of 
analytes, base line noise, formation of by-products, appearance of degradation products, or 
column obstruction.  Protein precipitation with acetonitrile  was also attempted, but recoveries of 
the analytes were very poor (Zorza et al., 2007). Poor recovery of vinca alkaloids might be due to 
high protein binding (Steele et al., 1983). In order to overcome different complications 
encountered in the aforementioned methods, solid phase extraction was examined using HLB and 
MCX cartridges. The solid-phase extraction (SPE) protocol using Oasis
®
 HLB cartridges 
provided the highest analyte recovery. To the authors’ knowledge, the use of HLB columns in 
extraction of vinblastine and desacetylvinblastine has not been previously published. However, 
among the vinca alkaloids, the use of HLB columns has been reported in metabolism studies of 
vinorelbine in several matrices (de Graeve et al., 2008). The HLB SPE cartridges were selected 
for investigation in the present study because their polymeric reversed phase materials give wide 
versatility for use with a variety of polar and non-polar drugs and can be allowed to  dry 





Different mobile phase compositions were explored to optimize the separation of analytes. Good 
separation and chromatography were achieved using isocratic elution with 10% 5 mM ammonium 
acetate (pH: 3.5) and 90% methanol at a flow rate of 0.75 mL/min.  No carryover of analytes in 
successive injected samples was observed. The absence of carryover was confirmed by injection 
of resuspending buffer after injection of the highest calibrant.  
Instrument settings and optimization 
Direct infusion of analytes was used to determine the optimal instrument parameters, such as 
nebulizing gas (gas1): 40; turbo ion spray (TIS, gas2): 20; temperature: 400 
0
C; collision energy 
(CE): 49 eV; collision cell exit potential (CXP): 8 V. Optimization of these parameters was 
important in removing or decreasing interferences in combination with chromatographic 
separation. Ion path for MS/MS detection of compounds was tuned by infusion of a mixture of all 
three analytes into the tandem mass spectrometry. For vinca alkaloids, electron spray ionization 
(ESI) is the most often used method of ionization. But ESI gave low sensitivity, poor resolution, 
and more baseline noise with ESI(Damen et al., 2010). In order to overcome these problems, 
atmospheric pressure chemical ionization (APCI) with positive mode ionization was used and 
gave satisfactory sensitivity. Few publications have described the use of APCI for the 
quantification of vincristine and vinblastine (Read and Black, 1999). In APCI, ionization occurs 
in the gas phase, unlike ESI, where ionization occurs in the liquid phase. General advantages of 
APCI include high ionization efficiency, low susceptibility to chemical interferences, and also, 
APCI is considered to be more robust method of ionization than ESI (Read and Black, 1999; 
Politi et al., 2006). Multiple reaction monitoring (MRM) was used as this is the superior method 
compared to single ion monitoring (SIM)  (Damen et al., 2010).  A typical fragment ion is 
selected in MRM while a single molecular ion is selected in SIM. Methods using MRM had 




Specificity was verified by looking at the identification (ID) ratios of qualifier ions for each 
analyte (table 1). ID ratios within ± 20% of mean of ID ratios were considered as an acceptable 
limit. For quantitation of analytes, major ions were chosen, such as 811.5/355.1 for vinblastine, 
769.4/355.1 for desacetylvinblastine, and 779.4/658.2 for vinorelbine.  The major fragment of 
vinblastine was 811.5 whereas previously reported major fragments for vinblastine were 751 and 
793 (Zhou et al., 2005; Trim et al., 2008). 
Calibration curve 
In order to obtain linear calibration curves within acceptable limits for vinblastine, two calibration 
curves were prepared in plasma. A wide range of vinblastine calibrants were included (0.125 
ng/mL to 100 ng/mL) in plasma to quantify the expected concentrations of vinblastine in both 
adult and juvenile dogs. A similar method of quantitation of vinblastine in human plasma using 
LC/APCI-MS was previously described  (Ramirez et al., 1997). However, the LOQ and range of 
calibration curves reported in this paper were lower and wider than the previous work. The 
concentrations of desacetylvinblastine in the incurred samples were within a small range and 
required only one calibration curve.  The accuracy of both vinblastine and desacetylvinblastine in 
all calibration curves were above 80% at the limit of quantitation and above 85% at higher 
concentrations. At least, six calibrators were retained for each calibration curve and calibrators 
having back calculated values more than 15% were removed from the curves. 
Method validation 
Matrix effects, recovery efficiency, and processing efficiency were calculated for each analyte in 
both matrices (Matuszewski et al., 2003). Recoveries of both vinblastine and desacetylvinblastine 
were lower in plasma as compared to urine (Table 2). This could be attributed to binding of both 
analytes to plasma proteins or to ion suppression (Steele et al., 1983; Matuszewski et al., 2003; 
Peters et al., 2007; Damen et al., 2008). 
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The intraday and interday precision of vinblastine and desacetylvinblastine in both matrices were 
within 8.6% (table 3 and 4). This low value indicates the repeatability of the developed method.  
The lowest value of the intraday and interday accuracy of both analytes in both matrices was 89% 
indicating good accuracy of the developed method. For both analytes, the coefficient of 
determination was greater than 0.99 in all validation experiments and in incurred sample analysis.  
Vinblastine and 4-O-deacetylvinblastine freeze-thaw stability in plasma samples processed after 
single thawing and double thawing were within acceptable limits (table 5).  
Sensitivity 
The sensitivity of the novel method was tested by both statistical and empirical approaches 
(figures 6 and 7). The sensitivity of the method based on the empirical approach was higher than 
that predicted by the statistical approach. The LLOQ of vinblastine and desacetylvinblastine were 
0.125 ng/mL and 0.125 ng/mL with the empirical approach, but were 0.45 ng/mL and 0.21 ng/mL 
with the statistical approach, respectively. Although the statistical method is useful for initial 
predictions of LOD and LLOQ values, the empirical method is able to more concretely define the 
LLOQ that meets the predetermined  acceptance criteria for these values (Armbruster et al., 
1994).      
Application to in vivo vinblastine pharmacokinetic study in dogs 
The vinblastine concentrations determined in vivo in dogs ranged from 0.8 to 51.1 ng/mL and 
0.45 to 884 ng/mL in plasma and urine samples, respectively. The desacetylvinblastine 
concentrations were ranged from 0.22 to 1.03 ng/mL and 0.25 to 30.2 ng/mL in plasma and urine 
samples. Figure 8 represents a typical pharmacokinetic profile of vinblastine sulfate in dogs. As 
seen in figure 8, the time course disposition of plasma concentrations of vinblastine in dogs was 
described. The concentrations of vinblastine and desacetylvinblastine were above LLOQ until 24 
hr plasma samples and 72 hr urine samples. The data from in vivo vinblastine pharmacokinetic 
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study was applied to the on-going studies to develop novel dosing equations in dogs to calculate 
the doses of anticancer drugs more accurately. 
Conclusions 
 
A highly sensitive, specific, and reliable analytical method to quantify the concentrations of 
vinblastine and its metabolite, desacetylvinblastine, in canine plasma and urine samples using 
liquid chromatography – atmospheric pressure chemical ionization – mass spectrometry was 
developed and validated. This newly described assay is highly reproducible.  The high sensitivity 
of the method would be particularly useful in determining the concentrations of vinblastine and 
its metabolite, desacetylvinblastine in small sized dogs and to study the pharmacokinetics of 
vinblastine and desacetylvinblastine in dogs.  The analytical method developed could be useful in 
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144.1 124.2 122.2 
224.1 144.1 457.2 
355.1 355.1 658.2 
 






VLB DVLB VRB VLB DVLB VRB 
Matrix effects 65.7 76.5 78.0 100.7 106.6 110.5 
Recovery efficiency 65.3 72.0 68.7 103.6 108.5 84.6 
Processing efficiency 42.9 55.1 53.6 104.4 115.7 93.5 
 
 
Table 2. Mean percentages of matrix effects, recovery efficiency, and process efficiency of 
extraction of plasma and urine samples fortified with vinblastine, desacetylvinblastine, and 
vinorelbine in triplicate ; fortified at the concentrations of 5 ng/mL vinblastine and 
desacetylvinblastine, and 10 ng/mL vinorelbine. The matrix effects, recovery efficiency, and 









Intraday precision and accuracy  
































































Table 3. Intraday accuracy and precision of analytes in plasma and urine were presented as mean 
±  standard deviation. The intraday accuracy and precision of both analytes in both matrices were 














Interday precision and accuracy 






































50 50.1 ± 4.5 8.4 95.3     
DVLB 









Table 4. The values of interday accuracy and precision of analytes in plasma and urine in seven 
runs over a period of nine months and 3 runs over a period of two moths, respectively were 
presented as mean ± standard deviation. The values of interday accuracy and precision of both 











 Freeze – thaw stability testing 







































Table 5.  Freeze – thaw stability of plasma samples fortified with vinblastine and 4-O-
desacetylvinblastine was tested by storing the samples at -80 
0
C in triplicate. One batch of 
samples were thawed once and another batch were thawed twice, and then samples were 
processed together to test the freeze-thaw stability. The analytes were stable for up to two freeze-



























Figure 2. Representative SRM traces of blank plasma (m/z 811.5/355.1) and vinblastine (m/z 
811.5/355.1) showing the specificity of vinblastine identification in plasma samples.  
Blank plasma 
m/z: 811.5/355.1 






Figure 3. Representative SRM traces of blank plasma (m/z 769.4/355.1) and desacetylvinblastine 












Figure 4. Representative SRM traces of blank urine (m/z 811.5/355.1) and urine fortified with 














Figure 5. Representative SRM traces of blank urine (m/z 769.4/355.1) and desacetylvinblastine 
extracted from urine fortified with desacetylvinblastine (m/z 769.4/355.1) showing the specificity 













Figure 6. Calibration curves of vinblastine in plasma, in triplicate, to determine the sensitivity of 
the method using the statistical approach. Quantitative ratio was calculated as ratio of peak area 





y = 0.054x - 0.0058 
R² = 0.99 
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y = 0.045x - 0.0021 

























Figure 7. Calibration curves of desacetylvinblastine in plasma samples in triplicate to determine 
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Figure 8. A representative time course disposition of vinblastine in a dog (10 kg body weight), 






































Anticancer drugs are characterized by a narrow therapeutic index and wide variability in 
therapeutic outcome and toxicity. Inappropriate dosing of anticancer drugs contributes to 
therapeutic failure, suboptimal outcomes, multi-drug resistance, and toxicity. Therefore, the doses 
of anticancer drugs should be calculated as accurate as possible from the initiation of treatment. 
Currently, the doses of most anticancer drugs are calculated as a direct proportion of  body 
surface area (BSA) (Pinkel, 1958). As there is  wide variation in the adult body weights of dogs, 
ranging from a 1 kg Chihuahua to a 100 kg St. Bernard, dogs represent the ideal species to 
examine the effect of intraspecific allometry on drug disposition. As with most drugs, the efficacy 
of anticancer agents correlates best with total drug exposure. Mathematically, drug exposure is 
calculated as the area under the plasma concentration versus time curve (AUC) (Moore and 
Erlichman, 1987; van den Bongard et al., 2000; Hempel and Boos, 2007). Total body clearance is 
the important pharmacokinetic parameter that affects drug exposure. Therefore, if the allometric 
factors influencing drug clearance are better understood, the dose required to produce a desired 
drug exposure can be accurately calculated. Physiologically based pharmacokinetic (PBPK) 
models are increasingly popular to predict absorption, distribution, metabolism, and excretion of 
a drug or a chemical compound. To predict the disposition of a drug using these PBPK models, 
accurate estimates of organ weights, blood flow through the organs, and estimates of 
pharmacokinetic parameters are needed. However, current estimates of organ weights, 
physiological parameters, and pharmacokinetic parameters are primarily available for standard-
sized, laboratory beagle dogs that don’t adequately predict these values over a wide range of 
canine breeds. With this background, we hypothesized that the concomitant consideration of body 
weight, gender, and ontogeny on organ physiology and drug handling will accurately predict the 
clearance of drugs. The objectives of this study were to determine the clearance of anticancer 
drugs by considering  anatomical, physiological, and pharmacokinetic parameters, to develop 
allometric equations for estimating organ weights, physiological parameters, and drug disposition 
for a wide range of body weights in dogs for PBPK modeling, and, ultimately, to optimize drug 
183 
 
exposure of anticancer drugs among disparate canine patients. In order to test our hypothesis, two 
model anticancer drugs, cisplatin and vinblastine, were selected as agents that are primarily 
dependent upon renal and hepatic clearance, respectively. 
 
Allometric scaling of renal clearance of cisplatin in dogs 
Cisplatin is a platinum containing alkylating agent that acts by establishing cross links 
between and within purine bases of DNA, thereby arresting DNA replication (Legendre et al., 
2000). Cisplatin is indicated for the treatment of variety of solid tumors in both veterinary and 
human medicine (Barabas et al., 2008; Fouladi et al., 2008; McDuffie et al., 2010). Cisplatin is 
primarily excreted through the kidneys and therefore will serve as a model anticancer drug for 
renally cleared anticancer drugs. Nephrotoxicity is the dose limiting toxicity of cisplatin. 
Carboplatin is a sister analogue of cisplatin with reduced nephrotoxicity (Hanigan et al., 2009). 
The doses of carboplatin were successfully normalized among human patients as a function of 
creatinine clearance and AUC using the formula: Dose = AUC (GFR + 25) (Calvert et al., 1989). 
Unfortunately, renal functional markers, such as glomerular filtration rate (GFR), did not 
correlate well with the clearance of cisplatin in several previous human studies (Peng et al., 1997; 
de Jongh et al., 2001). The poor standardization of cisplatin drug exposure in previous studies, 
combined with its primarily renal route of elimination, make the prediction of cisplatin 
disposition a worthwhile goal of improved drug dosing algorithms. To that end, studies were 
undertaken to investigate the allometric factors that underlie cisplatin clearance.  
Liver, kidney, and heart weights were collected from a total of 383 dogs, including 146 
juvenile and 237 adult dogs, from nearby urban animal shelters and from the Oklahoma Animal 
Disease Diagnostic Laboratory (OADDL), Stillwater, OK. Data collected from animal shelters 
was used as the training data set to develop allometric equations. The data collected from 
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OADDL was used as the validation data set to test the newly developed equations. In addition, 
the newly developed allometric equations were compared to the standard method of organ weight 
prediction, which uses a fixed proportion of body weight (Steward et al., 1975). Based on a priori 
inclusion criteria, a total of 167 dogs (juveniles and adults) were retained in the training data for 
kidney weights. Body weight and ontogeny significantly influenced kidney weights, whereas 




0.095 · ontogeny 
; R
2
 = 0.93, sy.x = 0.088 (where adult=0, juvenile=1).  The newly 
developed allometric equations were compared against the standard method, where estimates are 
a fixed proportion of body weights (1.13% for juveniles and 0.4% for adults). The residual plots 
and sum of absolute residuals for predicted kidney weights demonstrated that the newly 
developed allometric equations better predicted organ weights than did the fixed proportion 
approach.   
In vivo physiological and pharmacokinetic studies were conducted in ten intact male dogs 
(4 – 54 kg), including two juvenile dogs (8 – 12 week old, 4 – 5 kg). Inulin and para-
aminohippuric acid were used as markers for the determination of glomerular filtration rate 
(GFR) and effective renal plasma flow (ERPF) (Earle and Berliner, 1946; Mann and Kinter, 
1993). Cisplatin was administered as a constant rate infusion for 20 minutes at the dose rate of 1 
mg/kg body weight. Concentrations of platinum in plasma ultra-filtrate and urine samples were 
quantified by inductively coupled plasma mass spectrometry (ICP-MS). The data were analyzed 
compartmentally using the WinNonlin
®
 pharmacokinetic software program. Renal physiological 
parameters, total body clearance, and renal clearance of cisplatin were log10
 
transformed and 
regressed against log10 body weights. In contrast to previous findings in humans, the clearance of 
cisplatin was well correlated with glomerular filtration, with an allometric exponent similar to 
3/4
th
 power of standard allometry (Peng et al., 1997; de Jongh et al., 2001). The exponents of 
effective renal plasma flow and effective renal blood flow were similar to the 2/3 power of 
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intraspecific allometry. These findings demonstrated that the initial doses of cisplatin correlate 
well with GFR in dogs. The lack of correlation between GFR in previous studies may instead 
stem from alteration of cisplatin kinetics with subsequent doses of cisplatin or species-specific 
differences (Aleksunes et al., 2008). 
The allometric relationship between kidney weights, renal physiological parameters, 
cisplatin renal and total clearance and body weight suggests a common underlying basis for the 
allometry of kidney form and function. Furthermore, the initial dose of cisplatin followed 
standard allometry and correlated well with GFR in dogs. Pharmacokinetic studies with multiple 
doses of cisplatin in dogs would be needed to determine whether the clearance of cisplatin 
continues to correlate well with GFR with successive doses, or if subsequent doses affect its own 
clearance.   
Allometry of Hepatic Metabolism of Vinblastine in Dogs 
Mast cell tumors are one of the most common cutaneous tumors in all breeds and ages of 
dogs. Vinblastine and prednisone regimens are commonly used to treat mast cell tumors. 
However, while dogs tolerate these regimens well, their efficacy is less than 50% of treated dogs. 
The inverse relationship between efficacy and toxicity of anticancer agents suggests that dogs 
may be under-dosed by the currently used doses of vinblastine. Vinblastine is primarily 
metabolized by the liver and excreted through bile(de Lannoy et al., 1994). In order to understand 
the factors influencing the total body clearance of vinblastine, different aspects of anatomical, in 
vivo drug handling, and in vitro drug metabolism of vinblastine were studied in dogs.  
Based on a priori inclusion criteria, data was retained for 235 dogs (80 juveniles and 155 
adults) for multiple linear regressions of body weight, ontogeny, and gender against liver weights. 
Body weight and ontogeny significantly influenced liver weights, whereas gender did not. Liver 
weight depended on body weight and ontogeny with the following allometric equation: Liver wt 
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 = 0.93, sy.x = 0.094 (where adult=0, juvenile=1). The 
newly developed allometric equation was compared to the commonly used  fixed proportion 
approach, where liver weight is estimated as 3.5% of body weight (Steward et al., 1975). The 
newly developed allometric equation relating body weight and ontogeny to liver weight was 
tested in the validation data set by inspection of residual plots, and the sum of absolute residuals. 
Both residual plots and the sum of absolute residuals demonstrated that the allometric equation 
more accurately predicted liver weight as compared to the fixed proportion of body weight 
approach.  
An in vivo pharmacokinetic study of vinblastine disposition was performed in four adult 
intact male dogs (10 – 54 kg). Vinblastine was administered as a bolus dose at the rate of 0.075 
mg/kg body weight. The concentrations of vinblastine and its metabolite desacetylvinblastine in 
plasma and urine samples were quantified using a newly developed liquid 
chromatography/tandem mass spectrometry analytical method. The data were analyzed 
compartmentally using the WinNonlin
®
 pharmacokinetic software program. The total and hepatic 
clearance of vinblastine were log10 transformed and regressed against log10 (10) body weight. 
Total and hepatic clearances of vinblastine depended on body weight as: CLtotal = 21.6 BW
0.78
 , R² 




R² = 0.97, respectively.  
Concurrent with the collection of organ weights, liver samples were collected from 
twenty three adult dogs (2.3 – 54 kg). Hepatic microsomes were purified by homogenization 
followed by differential centrifugation using a previously published standard protocol (Schneider, 
1948). The concentrations of microsomal protein in microsomes were quantified using the 
Bradford protein assay  (Bradford, 1976). The density of cytochrome P450 enzymes in the 
microsomal samples was quantified using the ascorbate reduced dithionate difference spectra 
(Matsubara et al., 1976). The intrinsic clearance of vinblastine was quantified with the substrate 
depletion approach, by incubating 0.025 – 61.65 μM of vinblastine in microsomal samples (Jones 
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and Houston, 2004; Nath and Atkins, 2006). The concentrations of vinblastine were quantified 
using reversed phase high performance liquid chromatography. The data were analyzed by 
WinNonlin
®
 pharmacokinetic software program to obtain the values of the theoretical maximum 
rate of reaction (Vmax) and Michaelis constant (Km). The in vitro intrinsic clearance of vinblastine 
was calculated as the ratio of Vmax to Km. The in vitro intrinsic clearance of vinblastine was scaled 
to the whole animal in vivo intrinsic clearance of vinblastine using a scaling factor of 55 mg of 
microsomal protein per gram of liver (Smith et al., 2008). The in vivo intrinsic clearance of 
vinblastine was combined with physiological parameters, such as fraction of unbound drug and 
hepatic blood flow, to predict the hepatic clearance of vinblastine using several predictive 
models: the well stirred, parallel tube, and dispersion models (Pang and Rowland, 1977; Houston 
and Carlile, 1997). The hepatic clearance of vinblastine determined in vitro was compared to the 
in vivo hepatic clearance of vinblastine. For the first time, the allometric dependence of the 
density of cytochrome P450 enzymes on body weight was shown in dogs, confirming the 
allometric dependence of cellular metabolism on body size (Porter, 2001). The in vitro drug 
metabolism studies predicted hepatic clearance of vinblastine within 10 % of the measured in vivo 
values of hepatic clearance. Such in vitro/in vivo correlations could increase the utility of 
intraspecific allometric equations and decrease the number of live animal studies involved in drug 
development phases.  
In conclusion, the allometric equations developed for organ weights, physiological 
parameters, and the clearance of model anticancer drugs could be utilized in predictive 
pharmacokinetic models. Such models require the accurate input of key anatomical, 
physiological, and pharmacokinetic parameters to accurately standardize drug exposure in a 
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